CASEID,PRIMARYID,CASEVERSION,I_F_CODE,EVENT_DT,MFR_DT,INIT_FDA_DT,FDA_DT,REPT_COD,AUTH_NUM,MFR_NUM,MFR_SNDR,LIT_REF,AGE,AGE_COD,AGE_GRP,SEX,E_SUB,WT,WT_COD,REPT_DT,TO_MFR,OCCP_COD,REPORTER_COUNTRY,OCCR_COUNTRY,DRUGNAME,PT,PRIMARYID_OUTC,OUTC_COD,PRIMARYID_RPSR,RPSR_COD,PRIMARYID_THER,DSG_DRUG_SEQ,START_DT,END_DT,DUR,DUR_COD,PRIMARYID_INDI,INDI_DRUG_SEQ,INDI_PT
12985056,129850567,7,F,,20210726,20161129,20210804,EXP,,CA-APOTEX-2016AP014805,APOTEX,,52,YR,,M,Y,,,20210804,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,129850567,CA,,,,,,,,,129850567,1,HIV infection
13851390,138513904,4,F,,20210907,20170809,20210909,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-069840,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20210909,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,138513904,DE,,,,,,,,,138513904,1,HIV infection
13906408,1390640822,22,F,,20210907,20170825,20210909,EXP,,CA-009507513-0809CAN00001,MERCK,,54,YR,,M,Y,,,20210909,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,1390640822,OT,,,1390640822,1,20070620,,,,1390640822,1,HIV infection
14306973,1430697310,10,F,,20210728,20171220,20210809,EXP,,CA-APOTEX-2017AP022582,APOTEX,,54,YR,,M,Y,,,20210809,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Loss of personal independence in daily activities,1430697310,OT,,,,,,,,,1430697310,1,Bipolar disorder
15463860,154638607,7,F,2018,20210913,20181004,20210920,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2018GSK177825,VIIV,,,,,,Y,,,20210920,,MD,ZA,ZA,EFAVIRENZ.,Congenital umbilical hernia,154638607,CA,,,154638607,1,20180628,20200326,,,154638607,1,HIV infection
15573679,155736798,8,F,,20210723,20181101,20210802,EXP,,CA-TEVA-2018-CA-968128,TEVA,,54,YR,A,M,Y,,,20210802,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Loss of personal independence in daily activities,155736798,OT,,,,,,,,,155736798,1,HIV infection
15626751,1562675117,17,F,,20210923,20181116,20210924,EXP,,CA-ABBVIE-18S-028-2552613-00,ABBVIE,,54,YR,,M,Y,,,20210924,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,1562675117,DE,,,,,,,,,1562675117,1,HIV infection
15645707,156457073,3,F,201101,20210901,20181121,20210908,EXP,,US-GILEAD-2018-0375755,GILEAD,,60,YR,A,F,Y,65.76,KG,20210907,,CN,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Arthralgia;Cystitis;Dysstasia;Economic problem;Emotional distress;Mobility decreased;Nephropathy;Osteoporosis;Pain;Renal failure;Renal impairment,156457073,OT,,,156457073,1,201108,201407,,,156457073,1,HIV infection
15652130,156521303,3,F,20130513,20210906,20181123,20210910,EXP,,US-GILEAD-2018-0376062,GILEAD,,45,YR,A,F,Y,47.62,KG,20210910,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Gait disturbance;Osteopenia;Osteoporosis;Pain,156521303,OT,,,156521303,1,2011,2013,,,156521303,1,HIV infection
15831626,158316263,3,F,20110920,20210712,20190116,20210721,EXP,,US-ASTRAZENECA-2018SF14892,ASTRAZENECA,,18417,DY,,M,Y,68,KG,20210720,,,US,US,SUSTIVA,Acute kidney injury;Chronic kidney disease;End stage renal disease;Tubulointerstitial nephritis,158316263,OT,,,158316263,1,199811,201101,,,158316263,1,Gastrooesophageal reflux disease
15900940,159009403,3,F,2012,20210831,20190201,20210907,EXP,,US-GILEAD-2019-0387824,GILEAD,,60,YR,A,M,Y,82.09,KG,20210907,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Back pain;Bone density decreased;Bone disorder;Cervical vertebral fracture;Diabetes mellitus;Economic problem;Emotional distress;Fracture;Insomnia;Loss of personal independence in daily activities;Nephrolithiasis;Osteoporosis;Pain;Renal impairment;Tendon rupture;Upper limb fracture,159009403,OT,,,159009403,1,2004,2006,,,159009403,1,HIV infection
15998853,159988537,7,F,,20210430,20190223,20210712,EXP,,CA-009507513-1902CAN006364,MERCK,,52,YR,,M,Y,,,20210712,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Blood lactic acid increased;Diplopia;Dysphagia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,159988537,OT,,,,,,,,,159988537,1,HIV infection
16213144,162131445,5,F,20080619,20210623,20190418,20210701,EXP,,US-GILEAD-2019-0402581,GILEAD,,36,YR,A,M,Y,78.46,KG,20210701,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;Fracture;Hip fracture;Osteopenia;Pain;Renal failure;Tooth loss,162131445,OT,,,162131445,1,2008,2009,,,162131445,1,Acquired immunodeficiency syndrome
16277931,162779316,6,F,201606,20210726,20190506,20210730,EXP,,US-GILEAD-2019-0405253,GILEAD,,32,YR,A,F,Y,81.65,KG,20210730,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Bone density decreased;Chronic kidney disease;Depression;Economic problem;Emotional distress;End stage renal disease;Gait disturbance;Oedema peripheral;Pain;Renal failure;Tooth loss,162779316,HO,,,162779316,1,2011,201603,,,162779316,1,HIV infection
16340534,163405343,3,F,,20210818,20190522,20210830,EXP,,CA-AUROBINDO-AUR-APL-2019-027585,AUROBINDO,,54,YR,,M,Y,,,20210831,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,163405343,OT,,,,,,,,,163405343,1,HIV infection
16446145,164461456,6,F,,20210920,20190618,20210924,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2019GSK105240,VIIV,,54,YR,,M,Y,,,20210924,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,164461456,OT,,,,,,,,,164461456,1,HIV infection
16446152,164461526,6,F,,20210920,20190618,20210924,EXP,,CA-GLAXOSMITHKLINE-CA2019GSK105240,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20210924,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,164461526,DE,,,,,,,,,164461526,1,HIV infection
16542961,165429614,4,F,,20210716,20190709,20210730,EXP,,CA-AUROBINDO-AUR-APL-2019-037761,AUROBINDO,,54,YR,,M,Y,,,20210730,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,165429614,OT,,,,,,,,,165429614,1,Product used for unknown indication
16549468,165494683,3,F,,20210716,20190710,20210730,EXP,,CA-AUROBINDO-AUR-APL-2019-037814,AUROBINDO,,54,YR,,M,Y,,,20210730,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,165494683,OT,,,,,,,,,165494683,1,Bipolar disorder
16549483,165494834,4,F,,20210716,20190710,20210730,EXP,,CA-AUROBINDO-AUR-APL-2019-037892,AUROBINDO,,54,YR,,M,Y,,,20210730,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,165494834,OT,,,,,,,,,165494834,1,Product used for unknown indication
16549523,165495232,2,F,,20210716,20190710,20210730,EXP,,CA-AUROBINDO-AUR-APL-2019-038401,AUROBINDO,,54,YR,,M,Y,,,20210730,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,165495232,OT,,,,,,,,,165495232,1,Product used for unknown indication
16549598,165495982,2,F,,20210719,20190710,20210731,EXP,,CA-AUROBINDO-AUR-APL-2019-039459,AUROBINDO,,54,YR,,M,Y,,,20210731,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,165495982,OT,,,,,,,,,165495982,1,Bipolar disorder
16597483,165974836,6,F,2008,20210623,20190719,20210701,EXP,,US-GILEAD-2019-0418455,GILEAD,,52,YR,A,M,Y,,,20210701,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthritis;Back pain;Bone density decreased;Bone loss;Cervical radiculopathy;Cervical spinal stenosis;Depression;Drug ineffective;Economic problem;Emotional distress;Hip fracture;Intervertebral disc degeneration;Intervertebral disc operation;Mobility decreased;Multiple fractures;Osteonecrosis;Osteopenia;Osteoporotic fracture;Pain;Pathological fracture;Sacroiliac joint dysfunction;Spinal column injury;Spinal osteoarthritis;Spinal stenosis,165974836,OT,,,165974836,1,2004,2013,,,165974836,1,HIV infection
16623814,166238142,2,F,,20210716,20190724,20210730,EXP,,CA-AUROBINDO-AUR-APL-2019-042064,AUROBINDO,,54,YR,,M,Y,,,20210730,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,166238142,OT,,,,,,,,,166238142,1,Bipolar disorder
16636844,166368443,3,F,,20210908,20190726,20210913,EXP,,PT-MYLANLABS-2019M1069166,MYLAN,"MENDEZ, J.. EVALUATION OF THE POPULATION OF COINFECTED HCV/HIV PATIENT NON RESPONDANT TO DAAS.. PRESENTED AT CO?INFECTION PORTUGUESE STUDY GROUP.. 2019",43,YR,,M,Y,,,20210913,,MD,PT,PT,EFAVIRENZ.,Hepatitis C;Treatment failure,166368443,OT,,,,,,,,,166368443,1,Hepatitis C
16734269,167342696,6,F,,20210819,20190823,20210831,EXP,,CA-AUROBINDO-AUR-APL-2019-054545,AUROBINDO,,54,YR,,M,Y,,,20210831,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,167342696,OT,,,,,,,,,167342696,1,Bipolar disorder
16734610,167346102,2,F,,20210818,20190823,20210830,EXP,,CA-AUROBINDO-AUR-APL-2019-054681,AUROBINDO,,,,,M,Y,,,20210831,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,167346102,OT,,,,,,,,,167346102,1,Product used for unknown indication
16765373,167653735,5,F,20150829,20210924,20190903,20210929,EXP,,US-GILEAD-2019-0425747,GILEAD,,41,YR,A,M,Y,99.79,KG,20210929,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chest pain;Chronic kidney disease;Economic problem;Emotional distress;End stage renal disease;Headache;Loss of personal independence in daily activities;Pain,167653735,OT,,,167653735,1,2012,2017,,,167653735,1,HIV infection
16830668,168306684,4,F,,20210715,20190920,20210728,EXP,,AT-ROCHE-1061841,ROCHE,"TAYLOR N, TOUZEAU V, GEIT M, GISINGER M, EGLE A, GREIL R ET AL. RALTEGRAVIR IN PREGNANCY A CASE SERIES PRESENTATION. INTERNATIONAL JOURNAL OF STD ANSD AIDS. DOI:10.1258/IJSA.2011.010469 2011?22 (6):358?360.",39,YR,,F,Y,,,20210728,,MD,AT,AT,EFAVIRENZ.,Acute stress disorder;Maternal exposure during pregnancy;Premature delivery;Premature rupture of membranes;Rebound effect;Viral load increased,168306684,HO,,,,,,,,,168306684,1,HIV infection
16837989,168379894,4,F,20051230,20210729,20190923,20210802,EXP,,US-GILEAD-2019-0429311,GILEAD,,37,YR,A,M,Y,104.76,KG,20210802,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Decreased activity;Depression;Economic problem;Emotional distress;End stage renal disease;Fatigue;Hyperparathyroidism secondary;Loss of personal independence in daily activities;Pain;Quality of life decreased;Renal disorder;Renal failure;Renal neoplasm;Upper limb fracture,168379894,HO,,,168379894,1,200111,20060830,,,168379894,1,HIV infection
16843451,168434513,3,F,20100513,20210910,20190924,20210914,EXP,,US-GILEAD-2019-0429705,GILEAD,,62,YR,A,M,Y,133.79,KG,20210914,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Decreased activity;Emotional distress;Fracture;Kyphosis;Loss of personal independence in daily activities;Mobility decreased;Osteopenia;Osteoporosis;Pain;Quality of life decreased;Spinal compression fracture;Weight increased,168434513,OT,,,168434513,1,2002,2005,,,168434513,1,HIV infection
16850183,168501833,3,F,201511,20210728,20190925,20210805,EXP,,US-GILEAD-2019-0429207,GILEAD,,35,YR,A,F,Y,,,20210805,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Chronic kidney disease;Economic problem;Emotional distress;Hepatic enzyme increased;Multiple injuries;Pain;Renal failure,168501833,OT,,,168501833,1,20150817,20161102,,,168501833,1,HIV infection
16861811,168618114,4,F,201011,20210915,20190927,20210923,EXP,,US-GILEAD-2019-0429413,GILEAD,,55,YR,A,M,Y,45.35,KG,20210923,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Decreased activity;Economic problem;Emotional distress;Fatigue;Loss of personal independence in daily activities;Mobility decreased;Pain;Quality of life decreased,168618114,OT,,,168618114,1,200910,201011,,,168618114,1,HIV infection
16862241,168622413,3,F,201208,20210730,20190927,20210806,EXP,,US-GILEAD-2019-0429714,GILEAD,,39,YR,A,M,Y,71.2,KG,20210806,,CN,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Chronic kidney disease-mineral and bone disorder;Economic problem;Emotional distress;End stage renal disease;Fatigue;Fear-related avoidance of activities;Impaired work ability;Loss of personal independence in daily activities;Mobility decreased;Myocardial infarction;Nephrolithiasis;Osteopenia;Pain;Quality of life decreased;Renal cyst;Renal failure,168622413,OT,,,168622413,1,2011,2018,,,168622413,1,HIV infection
16970346,169703466,6,F,2008,20210719,20191029,20210726,EXP,,US-GILEAD-2019-0434731,GILEAD,,41,YR,A,F,Y,61.22,KG,20210726,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Bone density decreased;Depression;Economic problem;Emotional distress;Fanconi syndrome acquired;Fatigue;Glycosuria;Osteopenia;Osteoporosis;Pain;Pathological fracture;Proteinuria;Renal failure;Vitamin D decreased,169703466,OT,,,169703466,1,2001,2010,,,169703466,1,HIV infection
16972969,169729696,6,F,201706,20210923,20191030,20210929,EXP,,US-GILEAD-2019-0434698,GILEAD,,44,YR,A,M,Y,79.37,KG,20210929,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Depression;Economic problem;Emotional distress;Multiple fractures;Osteomalacia;Osteopenia;Pain;Rib fracture;Vitamin D deficiency,169729696,OT,,,169729696,1,200601,200701,,,169729696,1,HIV infection
17044956,170449563,3,F,,20210827,20191118,20210909,EXP,,CA-BAUSCH-BL-2019-058588,BAUSCH AND LOMB,,54,YR,,M,Y,,,20210909,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,170449563,DE,,,,,,,,,170449563,1,Bipolar disorder
17097939,170979394,4,F,2012,20210805,20191202,20210813,EXP,,US-GILEAD-2019-0440104,GILEAD,,,,A,M,Y,,,20210813,,CN,US,US,SUSTIVA,Arthralgia;Bone density abnormal;Bone density decreased;Bone loss;Hip arthroplasty;Joint arthroplasty;Multiple fractures;Osteonecrosis;Osteoporosis;Tooth fracture;Tooth loss,170979394,OT,,,170979394,1,2008,2008,,,170979394,1,HIV infection
17198087,171980875,5,F,,20210708,20191225,20210710,EXP,,CA-ROCHE-2500389,ROCHE,,54,YR,,M,Y,,,20210710,,HP,CA,CA,EFAVIRENZ.,Depression;Drug interaction;Loss of personal independence in daily activities,171980875,OT,,,,,,,,,171980875,1,Bipolar disorder
17244332,172443327,7,F,2007,20210805,20200107,20210813,EXP,,US-GILEAD-2019-0444850,GILEAD,,,,A,M,Y,86.17,KG,20210813,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Drug resistance;Economic problem;Emotional distress;Pain;Renal failure;Skeletal injury,172443327,OT,,,172443327,1,201302,201604,,,172443327,1,HIV infection
17244373,172443735,5,F,20151129,20210624,20200107,20210701,EXP,,US-GILEAD-2020-0445052,GILEAD,,50,YR,A,M,Y,64.85,KG,20210701,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;Fracture;Hip fracture;Nephrolithiasis;Osteoporosis;Pain,172443735,OT,,,172443735,1,201208,201610,,,172443735,1,HIV infection
17349167,173491675,5,F,201009,20210831,20200130,20210902,EXP,,US-GILEAD-2020-0448797,GILEAD,,36,YR,A,M,Y,79.37,KG,20210901,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Depression;Economic problem;Emotional distress;End stage renal disease;Pain;Renal failure,173491675,OT,,,173491675,1,2001,20170802,,,173491675,1,HIV infection
17571617,175716172,2,F,,20210817,20200323,20210826,EXP,,CA-TEVA-2020-CA-1207783,TEVA,,52,YR,A,M,Y,,,20210826,,HP,CA,CA,SUSTIVA,Blood lactic acid increased;Diplopia;Dysphagia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,175716172,OT,,,,,,,,,175716172,1,HIV infection
17584141,175841413,3,F,,20210729,20200326,20210810,EXP,,NG-CIPLA LTD.-2020NG02102,CIPLA,,,,,,Y,,,20210810,,HP,NG,NG,EFAVIRENZ.,Exposure during pregnancy,,,,,,,,,,,175841413,1,HIV infection
17705396,177053965,5,F,20080115,20210723,20200424,20210730,EXP,,US-GILEAD-2020-0460253,GILEAD,,47,YR,A,M,Y,49.89,KG,20210730,,CN,US,US,SUSTIVA,Bone density decreased;Bone loss;Chronic kidney disease;Economic problem;Emotional distress;Femoral neck fracture;Haematuria;Hip arthroplasty;Illness;Nausea;Osteoarthritis;Osteonecrosis;Osteopenia;Osteoporosis;Pain;Proteinuria;Renal failure;Rib fracture;Tooth loss,177053965,OT,,,177053965,1,2007,20090202,,,177053965,1,HIV infection
17714453,177144535,5,F,20040617,20210709,20200427,20210716,EXP,,US-GILEAD-2020-0460865,GILEAD,,33,YR,A,M,Y,73.02,KG,20210716,,CN,US,US,SUSTIVA,Acute kidney injury;Anxiety;Chronic kidney disease;Emotional distress;End stage renal disease;Hyperparathyroidism secondary;Mobility decreased;Pain;Renal cyst;Renal failure;Renal tubular necrosis,177144535,HO,,,177144535,1,20040112,20171023,,,177144535,1,HIV infection
17719478,177194784,4,F,2012,20210316,20200428,20210701,EXP,,US-GILEAD-2020-0460476,GILEAD,,46,YR,A,M,Y,77.1,KG,20210701,,LW,US,US,SUSTIVA,Bone density decreased;Bone loss;Cataract;Depression;Emotional distress;Insomnia;Intervertebral disc degeneration;Osteonecrosis;Osteopenia;Pain;Radiculopathy;Renal failure;Social anxiety disorder;Spinal osteoarthritis;Spinal stenosis,177194784,OT,,,177194784,1,20130730,20151022,,,177194784,1,HIV infection
17727228,177272286,6,F,20150102,20210909,20200430,20210914,EXP,,US-GILEAD-2020-0460881,GILEAD,,65,YR,E,F,Y,61.22,KG,20210914,,LW,US,US,SUSTIVA,Acute kidney injury;Azotaemia;Blood creatinine increased;Chronic kidney disease;Economic problem;Emotional distress;Fanconi syndrome acquired;Insomnia;Malaise;Pain;Pollakiuria;Renal disorder;Renal failure;Renal impairment;Renal tubular disorder,177272286,OT,,,177272286,1,20150904,20151021,,,177272286,1,HIV infection
17728731,177287313,3,F,201010,20210623,20200430,20210702,EXP,,US-GILEAD-2020-0462651,GILEAD,,36,YR,A,F,Y,83.45,KG,20210702,,CN,US,US,SUSTIVA,Chronic kidney disease;Depression;Dyspnoea;Emotional distress;End stage renal disease;Fatigue;Pain;Renal failure,177287313,OT,,,177287313,1,20141002,20141226,,,177287313,1,HIV infection
17751316,177513168,8,F,20130930,20210830,20200506,20210906,EXP,,US-GILEAD-2020-0464283,GILEAD,,63,YR,A,M,Y,86.18,KG,20210906,,CN,US,US,SUSTIVA,Acute kidney injury;Azotaemia;Chronic kidney disease;Chronic kidney disease-mineral and bone disorder;Clostridium difficile infection;Device related bacteraemia;Disorientation;Emotional distress;End stage renal disease;Feeling drunk;Hyperkalaemia;Hyperparathyroidism secondary;Intervertebral discitis;Lower limb fracture;Nephrogenic anaemia;Nightmare;Osteomyelitis;Osteopenia;Pain;Paranoia;Poor quality sleep;Renal failure;Renal tubular necrosis;Somnolence;Staphylococcal bacteraemia;Tibia fracture;Toxic encephalopathy,177513168,OT,,,177513168,1,20120512,20131013,,,177513168,1,HIV infection
17759277,177592773,3,F,,20210706,20200508,20210712,EXP,,CA-ROCHE-2485311,ROCHE,,45,YR,,M,Y,,,20210712,,HP,CA,CA,EFAVIRENZ.,Multiple-drug resistance,177592773,OT,,,,,,,,,177592773,1,HIV infection
17904368,179043684,4,F,20110301,20210707,20200617,20210713,EXP,,US-GILEAD-2020-0470173,GILEAD,,34,YR,A,F,Y,65.77,KG,20210713,,CN,US,US,SUSTIVA,Chronic kidney disease,179043684,OT,,,179043684,1,2004,,,,179043684,1,HIV infection
17904644,179046449,9,F,20020111,20210727,20200617,20210803,PER,,US-GILEAD-2020-0471554,GILEAD,,65,YR,E,M,Y,88.44,KG,20210803,,LW,US,US,SUSTIVA,Acute kidney injury;Blood creatinine increased;Chronic kidney disease;Drug ineffective;Fanconi syndrome acquired;Lumbar vertebral fracture;Multiple fractures;Nephropathy;Radiculopathy;Renal failure;Viral load increased,179046449,OT,,,179046449,1,20020111,20050525,,,179046449,1,HIV infection
17924422,179244224,4,F,2006,20210706,20200622,20210708,EXP,,US-GILEAD-2020-0474191,GILEAD,,57,YR,A,M,Y,104.31,KG,20210708,,LW,US,US,SUSTIVA,Acute kidney injury;Anaemia of chronic disease;Anhedonia;Anxiety;Bone density decreased;Bone metabolism disorder;Chronic kidney disease;Dyspnoea;Emotional distress;End stage renal disease;Erectile dysfunction;Focal segmental glomerulosclerosis;Hyperparathyroidism secondary;Loss of personal independence in daily activities;Pain;Proteinuria;Renal failure;Tooth loss,179244224,OT,,,179244224,1,2006,20120816,,,179244224,1,HIV infection
17936980,179369805,5,F,20121213,20210625,20200624,20210715,EXP,,US-GILEAD-2020-0475000,GILEAD,,52,YR,A,M,Y,,,20210714,,CN,US,US,SUSTIVA,Chronic kidney disease;Chronic kidney disease-mineral and bone disorder;Emotional distress;End stage renal disease;Nephropathy;Pain;Renal failure;Somnolence,179369805,OT,,,179369805,1,2005,200903,,,179369805,1,HIV infection
17949727,179497278,8,F,,20210913,20200626,20210923,EXP,CA-MHPD-E2B_02966351,CA-ACCORD-186554,ACCORD,,54,YR,,M,Y,,,20210923,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,179497278,DE,,,,,,,,,179497278,1,Bipolar disorder
17960294,179602947,7,F,201803,20210629,20200630,20210701,EXP,,US-GILEAD-2020-0476825,GILEAD,,52,YR,A,M,Y,68.03,KG,20210701,,LW,US,US,SUSTIVA,Bone density decreased;Emotional distress;Multiple fractures;Osteoporosis;Pain;Radius fracture;Spinal compression fracture;Spinal fracture;Tooth fracture;Tooth loss;Ulna fracture,179602947,OT,,,179602947,1,2006,20190819,,,179602947,1,HIV infection
17991249,179912496,6,F,201203,20210617,20200707,20210702,PER,,US-GILEAD-2020-0478868,GILEAD,,54,YR,A,M,Y,99.77,KG,20210702,,LW,US,US,SUSTIVA,Chronic kidney disease;Drug ineffective;Emotional distress;End stage renal disease;Glomerulonephritis membranous;Malaise;Pain,179912496,HO,,,179912496,1,2006,2014,,,179912496,1,HIV infection
18016136,180161364,4,F,,20210830,20200713,20210909,EXP,,CA-TEVA-2020-CA-1798833,TEVA,,54,YR,A,M,Y,,,20210909,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,180161364,DE,,,,,,,,,180161364,1,HIV infection
18065589,180655892,2,F,,20210908,20200724,20210921,EXP,CA-MHPD-E2B_02992182,CA-ACCORD-191476,ACCORD,,44,YR,,M,Y,,,20210921,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,180655892,OT,,,,,,,,,180655892,1,Depression
18103245,181032454,4,F,20180110,20210618,20200803,20210701,EXP,,US-GILEAD-2020-0487229,GILEAD,,67,YR,E,M,Y,56.24,KG,20210701,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Pain;Renal failure;Skeletal injury,181032454,OT,,,181032454,1,2001,2018,,,181032454,1,HIV infection
18120238,181202383,3,F,201504,20210913,20200806,20210919,EXP,,US-GILEAD-2020-0484417,GILEAD,,74,YR,E,M,Y,90.7,KG,20210919,,CN,US,US,SUSTIVA,Chronic kidney disease;Emotional distress;Gait disturbance;Nausea;Nephropathy;Pain;Renal cyst;Renal failure;Renal impairment,181202383,OT,,,181202383,1,2004,2013,,,181202383,1,HIV infection
18133299,181332993,3,F,,20210924,20200811,20210929,EXP,,FR-MYLANLABS-2020M1070646,MYLAN,,,,I,,Y,,,20210929,,MD,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Pachygyria,181332993,CA,,,,,,,,,181332993,1,HIV infection
18165528,181655284,4,F,20140207,20210902,20200818,20210910,PER,,US-GILEAD-2020-0489964,GILEAD,,51,YR,A,M,Y,91.16,KG,20210910,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Blindness;Blood creatinine increased;Chronic kidney disease;Emotional distress;Hypokinesia;Pain;Renal impairment,181655284,OT,,,181655284,1,200303,2012,,,181655284,1,HIV infection
18178260,181782603,3,F,2019,20210824,20200821,20210831,PER,,US-GILEAD-2020-0491252,GILEAD,,64,YR,A,M,Y,73.92,KG,20210831,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone pain;Depression;Emotional distress;Fear of falling;Hepatic function abnormal;Injury;Loss of personal independence in daily activities;Osteopenia;Pain,,,,,181782603,1,2004,201901,,,181782603,1,HIV infection
18179409,181794097,7,F,,20210727,20200821,20210811,EXP,,CA-ROCHE-2583896,ROCHE,,52,YR,,M,Y,,,20210811,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Blood lactic acid increased;Diplopia;Dysphagia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,181794097,OT,,,,,,,,,181794097,1,HIV infection
18181094,181810945,5,F,2002,20210922,20200821,20210928,PER,,US-GILEAD-2020-0491031,GILEAD,,,,A,F,Y,90.7,KG,20210928,,CN,US,US,SUSTIVA,Anxiety;Back pain;Blood creatinine increased;Bone pain;Chromaturia;Depression;Emotional distress;Groin pain;Hypertension;Nephropathy;Pain,,,,,181810945,1,20090612,20100217,,,181810945,1,HIV infection
18187253,181872534,4,F,,20210913,20200824,20210924,EXP,CA-MHPD-E2B_03070843,CA-ACCORD-196145,ACCORD,,,,,M,Y,,,20210924,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction,181872534,DE,,,,,,,,,181872534,1,Product used for unknown indication
18194619,181946195,5,F,,20210914,20200825,20210922,EXP,,CA-ASTRAZENECA-2020SF06767,ASTRAZENECA,,54,YR,,M,Y,,,20210922,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,181946195,OT,,,,,,,,,181946195,1,Bipolar disorder
18195354,181953545,5,F,2008,20210909,20200825,20210917,EXP,,US-GILEAD-2020-0490990,GILEAD,,47,YR,A,F,Y,53.06,KG,20210917,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Depression;Dysstasia;Emotional distress;Fanconi syndrome acquired;Foot fracture;Gait disturbance;Hip fracture;Metabolic acidosis;Multiple fractures;Nephrogenic anaemia;Osteoporosis;Pain;Renal impairment,181953545,HO,,,181953545,1,2006,2016,,,181953545,1,HIV infection
18210798,182107982,2,F,,20210916,20200830,20210924,EXP,,CA-ASTRAZENECA-2020SF09059,ASTRAZENECA,,54,YR,,M,Y,,,20210924,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,182107982,OT,,,,,,,,,182107982,1,Bipolar disorder
18223483,182234835,5,F,20131101,20210623,20200902,20210701,EXP,,US-GILEAD-2020-0492514,GILEAD,,50,YR,A,F,Y,99.79,KG,20210701,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;End stage renal disease;Pain;Renal failure,182234835,OT,,,182234835,1,20120118,20170122,,,182234835,1,HIV infection
18225618,182256182,2,F,,20210916,20200903,20210924,EXP,,CA-ASTRAZENECA-2020SF09863,ASTRAZENECA,,54,YR,,M,Y,,,20210924,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,182256182,OT,,,,,,,,,182256182,1,Product used for unknown indication
18349036,183490362,2,F,,20210719,20201006,20210730,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK189276,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20210730,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,183490362,OT,,,,,,,,,183490362,1,Product used for unknown indication
18349038,183490382,2,F,,20210719,20201006,20210730,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2018GSK189276,VIIV,,54,YR,,M,Y,,,20210730,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,183490382,OT,,,,,,,,,183490382,1,Product used for unknown indication
18349618,183496183,3,F,,20210719,20201006,20210730,EXP,,CA-GLAXOSMITHKLINE-CA2020GSK194023,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20210730,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,183496183,OT,,,,,,,,,183496183,1,Bipolar disorder
18349627,183496273,3,F,,20210719,20201006,20210730,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2020GSK194023,VIIV,,54,YR,,M,Y,,,20210730,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,183496273,OT,,,,,,,,,183496273,1,Bipolar disorder
18357718,183577184,4,F,,20210825,20201008,20210904,EXP,,ES-AUROBINDO-AUR-APL-2020-051068,AUROBINDO,,47,YR,,M,Y,,,20210904,,HP,ES,ES,EFAVIRENZ.,"Bipolar disorder;Cyclothymic disorder;Delirium;Hallucination, auditory;Insomnia;Mania;Persecutory delusion;Psychiatric decompensation;Psychotic disorder;Psychotic symptom;Substance-induced psychotic disorder;Suicidal ideation",183577184,OT,,,,,,,,,183577184,1,HIV infection
18495438,184954382,2,F,,20210916,20201112,20210924,EXP,,CA-ASTRAZENECA-2020SF45204,ASTRAZENECA,,54,YR,,M,Y,,,20210924,,HP,CA,CA,EFAVIRENZ.,Depression;Drug interaction;Loss of personal independence in daily activities,184954382,OT,,,,,,,,,184954382,1,Bipolar disorder
18654345,186543454,4,F,20200731,20210831,20201223,20210902,EXP,,ZA-GILEAD-2020-0494586,GILEAD,,40,YR,A,F,Y,70.7,KG,20210902,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy;Transaminases increased,186543454,OT,,,186543454,1,20170309,20200909,,,186543454,1,HIV infection
18682327,186823272,2,F,,20201215,20201229,20210716,PER,,US-009507513-2012USA008427,MERCK,,53,YR,,F,Y,,,20210716,,HP,US,US,EFAVIRENZ.,Off label use,,,,,,,,,,,186823272,1,Mucormycosis
18715970,187159704,4,F,,20210809,20210108,20210813,EXP,,NVSC2021IT002377,NOVARTIS,,57,YR,,F,Y,,,20210813,,HP,IT,IT,EFAVIRENZ.,Drug ineffective;Graft versus host disease in skin;Human herpesvirus 6 infection reactivation;Pancytopenia;Pneumonia bacterial;Product use in unapproved indication,187159704,OT,,,,,,,,,187159704,1,Prophylaxis against graft versus host disease
18855729,188557294,4,F,,20210805,20210205,20210810,EXP,,AU-GILEAD-2021-0516233,GILEAD,,52,YR,A,F,Y,,,20210810,,HP,AU,AU,EFAVIRENZ.,Behaviour disorder;Central nervous system inflammation;Cerebellar syndrome;Chorea;Confusional state;Disorientation;Dysarthria;Dysdiadochokinesis;Gait disturbance;HIV-associated neurocognitive disorder;Hypophagia;Loss of personal independence in daily activities;Magnetic resonance imaging abnormal;Meningitis viral;Meningoencephalitis viral;Parainfluenzae virus infection;Past-pointing;Pathogen resistance;Rhinitis;Treatment noncompliance;Viraemia;Viral mutation identified,188557294,HO,,,,,,,,,188557294,1,HIV infection
18874254,188742542,2,F,,20210708,20210210,20210710,EXP,,CA-ROCHE-2765397,ROCHE,,54,YR,,M,Y,,,20210710,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,188742542,OT,,,,,,,,,188742542,1,Product used for unknown indication
18875824,188758242,2,F,200604,20210803,20210211,20210818,EXP,,US-GILEAD-2021-0515554,GILEAD,,45,YR,A,M,Y,66.67,KG,20210818,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine abnormal;Emotional distress;Multiple fractures;Osteoporosis;Pain;Proteinuria;Rib fracture;Road traffic accident,188758242,HO,,,188758242,1,2009,2016,,,188758242,1,HIV infection
18888983,188889832,2,F,2012,20210803,20210213,20210811,EXP,,US-GILEAD-2021-0515568,GILEAD,,,,A,F,Y,74.83,KG,20210811,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Dysstasia;Emotional distress;Fanconi syndrome acquired;Femur fracture;Foot fracture;Gait disturbance;Hip fracture;Multiple fractures;Osteomalacia;Pain,188889832,OT,,,188889832,1,2006,201408,,,188889832,1,HIV infection
18893076,188930763,3,F,,20210705,20210215,20210707,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013005,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20210707,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,188930763,DE,,,,,,,,,188930763,1,HIV infection
18920668,189206682,2,F,,20210803,20210222,20210810,EXP,,CA-ROCHE-2772982,ROCHE,,54,YR,,M,Y,,,20210810,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,189206682,OT,,,,,,,,,189206682,1,Bipolar disorder
18921190,189211902,2,F,,20210705,20210222,20210712,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013147,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20210712,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,189211902,OT,,,,,,,,,189211902,1,HIV infection
18923889,189238892,2,F,,20210705,20210222,20210709,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013552,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20210709,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,189238892,OT,,,,,,,,,189238892,1,Product used for unknown indication
18924449,189244492,2,F,,20210809,20210222,20210818,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013816,BRISTOL MYERS SQUIBB,,44,YR,,M,Y,,,20210818,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,189244492,OT,,,,,,,,,189244492,1,HIV infection
18928015,189280153,3,F,2015,20210811,20210223,20210818,PER,,US-GILEAD-2021-0517985,GILEAD,,,,A,F,Y,83.92,KG,20210818,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Cough;Drug resistance;Emotional distress;Osteopenia;Pain;Rib fracture;Wrist fracture,189280153,OT,,,189280153,1,2006,2010,,,189280153,1,HIV infection
18930094,189300942,2,F,,20210719,20210223,20210726,EXP,,CA-BAUSCH-BL-2021-005970,BAUSCH AND LOMB,,54,YR,,M,Y,,,20210726,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,189300942,OT,,,,,,,,,189300942,1,Bipolar disorder
18930107,189301073,3,F,,20210719,20210223,20210726,EXP,,CA-BAUSCH-BL-2021-006006,BAUSCH AND LOMB,,54,YR,,M,Y,,,20210726,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,189301073,OT,,,,,,,,,189301073,1,Bipolar disorder
18930168,189301682,2,F,,20210719,20210223,20210726,EXP,,CA-BAUSCH-BL-2021-006106,BAUSCH AND LOMB,,54,YR,,M,Y,,,20210726,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,189301682,OT,,,,,,,,,189301682,1,Bipolar disorder
18932495,189324952,2,F,200906,20210924,20210224,20210930,EXP,,US-GILEAD-2021-0517968,GILEAD,,42,YR,A,M,Y,81.65,KG,20210930,,LW,US,US,SUSTIVA,Abdominal discomfort;Abnormal dreams;Anhedonia;Anxiety;Bone density decreased;Bone disorder;Bone loss;Decreased appetite;Emotional distress;Femur fracture;Hand fracture;Lower limb fracture;Osteopenia;Pain;Road traffic accident;Weight decreased,189324952,OT,,,189324952,1,2001,2005,,,189324952,1,HIV infection
18947793,189477932,2,F,,20210621,20210226,20210702,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021GSK053518,VIIV,,54,YR,,M,Y,,,20210702,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,189477932,OT,,,,,,,,,189477932,1,Bipolar disorder
18947871,189478712,2,F,,20210621,20210226,20210702,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK053518,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20210702,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,189478712,OT,,,,,,,,,189478712,1,Bipolar disorder
18954097,189540972,2,F,,20210719,20210301,20210730,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021GSK053762,VIIV,,54,YR,,M,Y,,,20210730,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,189540972,OT,,,,,,,,,189540972,1,Bipolar disorder
18954098,189540982,2,F,,20210719,20210301,20210729,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021GSK053527,VIIV,,54,YR,,M,Y,,,20210729,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,189540982,OT,,,,,,,,,189540982,1,Bipolar disorder
18954101,189541012,2,F,,20210719,20210301,20210729,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021GSK053625,VIIV,,,,,M,Y,,,20210729,,CN,CA,CA,EFAVIRENZ.,Depression;Drug interaction,189541012,OT,,,,,,,,,189541012,1,Product used for unknown indication
18954102,189541022,2,F,,20210719,20210301,20210729,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021GSK053470,VIIV,,54,YR,,M,Y,,,20210729,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,189541022,OT,,,,,,,,,189541022,1,Bipolar disorder
18954113,189541132,2,F,,20210719,20210301,20210729,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK053625,GLAXOSMITHKLINE,,,,,M,Y,,,20210729,,CN,CA,CA,EFAVIRENZ.,Depression;Drug interaction,189541132,OT,,,,,,,,,189541132,1,Product used for unknown indication
18954120,189541202,2,F,,20210719,20210301,20210729,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK053527,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20210729,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,189541202,OT,,,,,,,,,189541202,1,Bipolar disorder
18954146,189541462,2,F,,20210719,20210301,20210729,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK053470,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20210729,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,189541462,OT,,,,,,,,,189541462,1,Bipolar disorder
18954149,189541492,2,F,,20210719,20210301,20210730,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK053762,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20210730,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,189541492,OT,,,,,,,,,189541492,1,Bipolar disorder
18958016,189580162,2,F,,20210719,20210302,20210730,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021GSK053430,VIIV,,54,YR,,M,Y,,,20210730,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,189580162,OT,,,,,,,,,189580162,1,Bipolar disorder
18958132,189581322,2,F,,20210719,20210302,20210730,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK053430,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20210730,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,189581322,OT,,,,,,,,,189581322,1,Bipolar disorder
18958429,189584292,2,F,,20210719,20210302,20210729,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021GSK053531,VIIV,,54,YR,,M,Y,,,20210729,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,189584292,OT,,,,,,,,,189584292,1,Bipolar disorder
18958430,189584302,2,F,,20210719,20210302,20210729,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021GSK053512,VIIV,,54,YR,,M,Y,,,20210729,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,189584302,OT,,,,,,,,,189584302,1,Bipolar disorder
18958433,189584332,2,F,,20210719,20210302,20210729,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK053512,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20210729,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,189584332,OT,,,,,,,,,189584332,1,Bipolar disorder
18958434,189584342,2,F,,20210719,20210302,20210729,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK053531,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20210729,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,189584342,OT,,,,,,,,,189584342,1,Bipolar disorder
18959387,189593872,2,F,,20210719,20210302,20210729,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021GSK053576,VIIV,,54,YR,,M,Y,,,20210729,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,189593872,OT,,,,,,,,,189593872,1,Bipolar disorder
18959400,189594002,2,F,,20210719,20210302,20210729,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK053576,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20210729,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,189594002,OT,,,,,,,,,189594002,1,Bipolar disorder
18962597,189625972,2,F,,20210719,20210303,20210730,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021GSK053501,VIIV,,54,YR,,M,Y,,,20210730,,CN,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,189625972,OT,,,,,,,,,189625972,1,Bipolar disorder
18962600,189626003,3,F,,20210719,20210303,20210729,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021GSK053494,VIIV,,54,YR,,M,Y,,,20210729,,CN,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,189626003,OT,,,,,,,,,189626003,1,Bipolar disorder
18962611,189626113,3,F,,20210719,20210303,20210729,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK053494,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20210729,,CN,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,189626113,OT,,,,,,,,,189626113,1,Bipolar disorder
18962619,189626192,2,F,,20210719,20210303,20210730,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK053501,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20210730,,CN,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,189626192,OT,,,,,,,,,189626192,1,Bipolar disorder
18965775,189657752,2,F,,20210719,20210303,20210729,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021GSK053649,VIIV,,54,YR,,M,Y,,,20210729,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,189657752,OT,,,,,,,,,189657752,1,Bipolar disorder
18965890,189658902,2,F,,20210719,20210303,20210729,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK053649,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20210729,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,189658902,OT,,,,,,,,,189658902,1,Bipolar disorder
18975810,189758102,2,F,2004,20210927,20210305,20210930,EXP,,US-GILEAD-2021-0519262,GILEAD,,,,E,M,Y,86.17,KG,20210930,,LW,US,US,SUSTIVA,Anger;Anhedonia;Anxiety;Chronic kidney disease;Decreased appetite;Depression;Emotional distress;Fatigue;Pain;Peripheral swelling;Renal failure;Suicidal ideation,189758102,OT,,,189758102,1,2001,20080201,,,189758102,1,HIV infection
18980075,189800752,2,F,201010,20210224,20210308,20210909,EXP,,US-GILEAD-2021-0519282,GILEAD,,52,YR,A,M,Y,74.83,KG,20210909,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Arteriosclerosis coronary artery;Bone density decreased;Chronic kidney disease;Emotional distress;Osteopenia;Osteoporosis;Pain;Renal disorder;Renal impairment,189800752,OT,,,189800752,1,20090210,20130209,,,189800752,1,HIV infection
18981519,189815192,2,F,,20210805,20210308,20210810,EXP,,CA-ROCHE-2783000,ROCHE,,54,YR,,M,Y,,,20210810,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,189815192,OT,,,,,,,,,189815192,1,Bipolar disorder
18985241,189852412,2,F,,20210826,20210309,20210901,EXP,,CA-ROCHE-2783515,ROCHE,,54,YR,,M,Y,,,20210901,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,189852412,DE,,,,,,,,,189852412,1,Bipolar disorder
18986747,189867472,2,F,20180711,20210920,20210309,20210928,EXP,,US-GILEAD-2021-0519942,GILEAD,,55,YR,A,F,Y,86.17,KG,20210928,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Depression;Emotional distress;Fatigue;Hip fracture;Multiple fractures;Osteoporosis;Pain;Spinal compression fracture,189867472,OT,,,189867472,1,2010,2019,,,189867472,1,HIV infection
19019108,190191083,3,F,,20210830,20210316,20210909,EXP,,CA-TEVA-2021-CA-1889831,TEVA,,54,YR,A,M,Y,,,20210909,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,190191083,OT,,,,,,,,,190191083,1,HIV infection
19019110,190191103,3,F,,20210830,20210316,20210908,EXP,,CA-TEVA-2021-CA-1890032,TEVA,,54,YR,A,M,Y,,,20210908,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,190191103,OT,,,,,,,,,190191103,1,HIV infection
19019479,190194792,2,F,20120402,20210818,20210316,20210823,EXP,,US-GILEAD-2021-0520123,GILEAD,,51,YR,A,M,Y,82.55,KG,20210823,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Bone density decreased;Chronic kidney disease;Decreased interest;Emotional distress;Osteopenia;Osteoporosis;Pain;Proteinuria;Renal impairment;Rib fracture;Sleep disorder;Upper limb fracture,190194792,OT,,,190194792,1,2006,20120611,,,190194792,1,HIV infection
19047220,190472202,2,F,2007,20210909,20210323,20210921,EXP,,US-GILEAD-2021-0522286,GILEAD,,,,A,M,Y,86.17,KG,20210921,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Cyst;Depression;Dysstasia;Emotional distress;Femoral neck fracture;Foot fracture;Gait disturbance;Hand fracture;Hip fracture;Osteoporosis;Pain,190472202,OT,,,190472202,1,20041201,201908,,,190472202,1,HIV infection
19048139,190481392,2,F,200208,20210921,20210324,20210927,EXP,,US-GILEAD-2021-0522309,GILEAD,,48,YR,A,M,Y,68.93,KG,20210927,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Bone density decreased;Depression;Emotional distress;Foot fracture;Gait disturbance;Hand fracture;Mobility decreased;Osteoporosis;Pain;Physical deconditioning;Spinal compression fracture;Tibia fracture,190481392,OT,,,190481392,1,2004,201801,,,190481392,1,HIV infection
19061485,190614852,2,F,20120320,20210809,20210325,20210815,EXP,,US-GILEAD-2021-0522288,GILEAD,,,,,M,Y,97.07,KG,20210815,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Emotional distress;Osteoarthritis;Osteoporosis;Pain;Patella fracture;Protein urine present,190614852,OT,,,190614852,1,20081031,2006,,,190614852,1,HIV infection
19074794,190747942,2,F,2018,20210917,20210330,20210923,EXP,,US-GILEAD-2021-0523126,GILEAD,,,,A,M,Y,113.38,KG,20210923,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Fatigue;Hypokinesia;Pain;Pollakiuria,190747942,OT,,,190747942,1,20090609,20101114,,,190747942,1,HIV infection
19075820,190758202,2,F,201512,20210730,20210330,20210808,PER,,US-GILEAD-2021-0523103,GILEAD,,55,YR,A,M,Y,100.68,KG,20210807,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Dysstasia;Emotional distress;Gait disturbance;Pain;Renal failure,190758202,OT,,,190758202,1,2009,2006,,,190758202,1,HIV infection
19075896,190758962,2,F,2016,20210916,20210330,20210923,EXP,,US-GILEAD-2021-0523094,GILEAD,,,,A,F,Y,83.45,KG,20210923,,LW,US,US,EFAVIRENZ.;SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Chronic kidney disease-mineral and bone disorder;Dyspnoea;Emotional distress;Pain;Quality of life decreased;Renal failure,190758962,OT,,,190758962,1,2015,201909,,,190758962,1,HIV infection
19080655,190806552,2,F,2009,20210913,20210331,20210920,EXP,,US-GILEAD-2021-0523123,GILEAD,,52,YR,A,M,Y,110,KG,20210920,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Dysstasia;Emotional distress;Gait disturbance;Hip arthroplasty;Joint range of motion decreased;Osteopenia;Osteoporosis;Pain;Shoulder arthroplasty;Skeletal injury;Spinal fracture,190806552,OT,,,190806552,1,2003,201504,,,190806552,1,HIV infection
19081584,190815844,4,F,,20210916,20210331,20210924,EXP,,CA-ASTRAZENECA-2020SF04539,ASTRAZENECA,,44,YR,,M,Y,,,20210924,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,190815844,HO,,,,,,,,,190815844,1,Depression
19132855,191328552,2,F,2018,20210917,20210413,20210924,PER,,US-GILEAD-2021-0524831,GILEAD,,,,E,F,Y,90.7,KG,20210924,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Drug ineffective;Emotional distress;Fatigue;Hypertension;Nephropathy;Pain;Renal failure;Renal impairment,191328552,OT,,,191328552,1,2001,2018,,,191328552,1,HIV infection
19132976,191329762,2,F,2009,20210908,20210413,20210913,EXP,,US-GILEAD-2021-0524855,GILEAD,,52,YR,A,M,Y,80.73,KG,20210913,,LW,US,US,SUSTIVA,Amnesia;Anhedonia;Anxiety;Asthenia;Chronic kidney disease;Depression;Emotional distress;Exercise tolerance decreased;Fatigue;Feeling abnormal;Flatulence;Insomnia;Memory impairment;Pain;Pollakiuria;Renal impairment;Suicide attempt;Urinary retention,191329762,OT,,,191329762,1,2004,2006,,,191329762,1,HIV infection
19134529,191345293,3,F,,20210823,20210414,20210924,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021GSK079642,VIIV,,54,YR,,M,Y,,,20210924,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,191345293,OT,,,,,,,,,191345293,1,Bipolar disorder
19134538,191345383,3,F,,20210823,20210414,20210924,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK079642,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20210924,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,191345383,OT,,,,,,,,,191345383,1,Bipolar disorder
19137612,191376122,2,F,2009,20210730,20210414,20210806,EXP,,US-GILEAD-2021-0524852,GILEAD,,40,YR,A,M,Y,142,KG,20210806,,CN,US,US,EFAVIRENZ.;SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Emotional distress;Foot fracture;Pain,191376122,OT,,,191376122,1,200805,,,,191376122,1,HIV infection
19139533,191395333,3,F,,20210823,20210415,20210924,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK079651,GLAXOSMITHKLINE,,,,,M,Y,,,20210924,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,191395333,HO,,,,,,,,,191395333,1,Product used for unknown indication
19139535,191395353,3,F,,20210823,20210415,20210924,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021GSK079651,VIIV,,,,,M,Y,,,20210924,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,191395353,HO,,,,,,,,,191395353,1,Product used for unknown indication
19153791,191537913,3,F,,20210823,20210419,20210924,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK079633,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20210924,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,191537913,OT,,,,,,,,,191537913,1,Bipolar disorder
19153924,191539243,3,F,,20210823,20210419,20210924,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021GSK079633,VIIV,,54,YR,,M,Y,,,20210924,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,191539243,OT,,,,,,,,,191539243,1,Bipolar disorder
19168493,191684935,5,F,20210410,20210705,20210422,20210716,EXP,,IN-CIPLA LTD.-2021IN02971,CIPLA,,,,,,Y,,,20210716,,MD,IN,IN,EFAVIRENZ/LAMIVUDINE/TENOFOVIR;EFAVIRENZ/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE,COVID-19,191684935,HO,,,191684935,2,20210309,20210309,,,191684935,1,Drug level
19172980,191729804,4,F,20210409,20210705,20210423,20210715,EXP,,IN-CIPLA LTD.-2021IN02956,CIPLA,,,,,,Y,,,20210715,,MD,IN,IN,EFAVIRENZ/LAMIVUDINE/TENOFOVIR;EFAVIRENZ/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE,COVID-19,191729804,HO,,,191729804,2,20210309,20210309,,,191729804,1,Drug level
19192355,191923552,2,F,,20210818,20210429,20210831,EXP,,CA-AUROBINDO-AUR-APL-2021-016522,AUROBINDO,,54,YR,,M,Y,,,20210831,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,191923552,OT,,,,,,,,,191923552,1,HIV infection
19192961,191929613,3,F,20210416,20210705,20210429,20210715,EXP,,IN-CIPLA LTD.-2021IN03006,CIPLA,,,,,,Y,,,20210715,,MD,IN,IN,EFAVIRENZ/LAMIVUDINE/TENOFOVIR;EFAVIRENZ/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE,COVID-19,191929613,HO,,,191929613,2,20210315,20210315,,,191929613,1,Drug level
19197847,191978473,3,F,20210416,20210705,20210430,20210715,EXP,,IN-CIPLA LTD.-2021IN03020,CIPLA,,,,,,Y,,,20210715,,MD,IN,IN,EFAVIRENZ/LAMIVUDINE/TENOFOVIR;EFAVIRENZ/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE,COVID-19,191978473,HO,,,191978473,2,20210315,20210315,,,191978473,1,Drug level
19199998,191999982,2,F,,20210823,20210430,20210830,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021GSK093546,VIIV,,54,YR,,M,Y,,,20210830,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,191999982,OT,,,,,,,,,191999982,1,Bipolar disorder
19200091,192000912,2,F,,20210823,20210430,20210830,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK093546,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20210830,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,192000912,OT,,,,,,,,,192000912,1,Bipolar disorder
19208184,192081842,2,F,,20210920,20210503,20210927,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021GSK093641,VIIV,,54,YR,,M,Y,,,20210927,,HP,CA,CA,EFAVIRENZ.,Depression;Drug interaction;Loss of personal independence in daily activities,192081842,OT,,,,,,,,,192081842,1,HIV infection
19208192,192081922,2,F,,20210920,20210503,20210927,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK093641,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20210927,,HP,CA,CA,EFAVIRENZ.,Depression;Drug interaction;Loss of personal independence in daily activities,192081922,OT,,,,,,,,,192081922,1,HIV infection
19214814,192148142,2,F,2016,20210921,20210504,20210928,PER,,US-GILEAD-2021-0527867,GILEAD,,,,A,M,Y,63,KG,20210928,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Depression;Emotional distress;Osteopenia;Pain,,,,,192148142,1,2004,2009,,,192148142,1,HIV infection
19215171,192151712,2,F,20190614,20210809,20210504,20210819,EXP,,US-GILEAD-2021-0527872,GILEAD,,63,YR,A,M,Y,113.38,KG,20210819,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Dyspareunia;Emotional distress;Gait disturbance;Insomnia;Osteoporosis;Pain;Physical disability;Spinal fracture,192151712,OT,,,192151712,1,2004,202009,,,192151712,1,HIV infection
19220333,192203333,3,F,20190225,20210714,20210506,20210726,PER,,US-GILEAD-2021-0527870,GILEAD,,53,YR,A,M,Y,140.59,KG,20210726,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone loss;Emotional distress;Fatigue;Osteopenia;Osteoporosis;Pain;Renal injury,192203333,OT,,,192203333,1,2002,201902,,,192203333,1,HIV infection
19263941,192639412,2,F,,20210701,20210517,20210706,EXP,,AU-ABBVIE-21K-008-3900310-00,ABBVIE,,,,,F,Y,,,20210706,,CN,AU,AU,EFAVIRENZ.,Behaviour disorder;Central nervous system inflammation;Cerebellar syndrome;Chorea;Confusional state;Disorientation;Dysarthria;Dysdiadochokinesis;Gait disturbance;HIV-associated neurocognitive disorder;Hypophagia;Loss of personal independence in daily activities;Magnetic resonance imaging head abnormal;Meningitis viral;Meningoencephalitis viral;Parainfluenzae virus infection;Pathogen resistance;Rhinitis;Treatment noncompliance;Viral mutation identified,192639412,OT,,,,,,,,,192639412,1,Product used for unknown indication
19312818,193128182,2,F,,20210728,20210527,20210810,EXP,,CA-APOTEX-2021AP012394,APOTEX,,,,,M,Y,,,20210810,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,193128182,HO,,,,,,,,,193128182,1,Product used for unknown indication
19399734,193997342,2,F,20201125,20210804,20210610,20210809,EXP,,FR-MYLANLABS-2021M1033868,MYLAN,,57,YR,,M,Y,60,KG,20210809,,MD,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective;Drug interaction;Viral load increased,193997342,OT,,,,,,,,,193997342,1,HIV infection
19406148,194061483,3,F,2016,20210719,20210611,20210728,EXP,,LV-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-054655,BRISTOL MYERS SQUIBB,,45,YR,,F,Y,,,20210728,,MD,LV,LV,EFAVIRENZ.,Blood cholesterol abnormal;Blood triglycerides abnormal;Coronary artery disease;Dizziness;High density lipoprotein abnormal;Hyperhidrosis;Hyperlipidaemia;Low density lipoprotein abnormal;Nightmare;Pulmonary hypertension,194061483,OT,,,194061483,1,2015,2016,,,194061483,1,HIV infection
19413580,194135802,2,F,,20210809,20210614,20210817,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-055982,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20210817,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,194135802,HO,,,,,,,,,194135802,1,Product used for unknown indication
19451744,194517442,2,F,,20210624,20210623,20210706,EXP,,GB-AUROBINDO-AUR-APL-2021-025521,AUROBINDO,,76,YR,,M,Y,,,20210706,,CN,GB,GB,EFAVIRENZ.,Renal impairment,194517442,OT,,,194517442,1,20121101,,,,194517442,1,HIV infection
19451767,194517673,3,F,2019,20210622,20210623,20210702,EXP,,DK-AUROBINDO-AUR-APL-2021-025770,AUROBINDO,,61,YR,,M,Y,,,20210702,,HP,DK,DK,EFAVIRENZ.,Dizziness;Drug ineffective;Headache;Intracranial pressure increased;Leukocytosis;Macular oedema;Nausea;Night sweats;Optic disc haemorrhage;Papilloedema;Pleocytosis;Pyrexia;Retinal exudates;Retroviral rebound syndrome;Vision blurred;Visual field defect;Vomiting;Weight decreased,194517673,OT,,,194517673,1,2015,,,,194517673,1,HIV infection
19451888,194518882,2,F,,20210624,20210623,20210705,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-057650,BRISTOL MYERS SQUIBB,,76,YR,,M,Y,,,20210705,,MD,GB,GB,EFAVIRENZ.,Renal impairment,194518882,OT,,,194518882,1,20121101,,,,194518882,1,HIV infection
19461093,194610934,4,F,,20210909,20210625,20210920,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-059435,BRISTOL MYERS SQUIBB,"ARAGONES EROLES AM, SCHOENENBERGER ARNAIZ JA, CANOMARRON SM, PUIG GANAU T, MORALES PORTILLO A, MANONELLES FERNANDEZ A. RELATIONSHIP BETWEEN PLASMA LEVELS OF EFAVIRENZ AND LIPEMIC ALTERATIONS. REV.OFIL.ILAPHAR. 2021?31(1):64?9",,,A,,Y,,,20210920,,MD,ES,ES,EFAVIRENZ.,Hypertension;Thrombosis,194610934,OT,,,,,,,,,194610934,1,Antiretroviral therapy
19464465,194644653,3,F,,20210714,20210626,20210727,EXP,,ES-AUROBINDO-AUR-APL-2021-026748,AUROBINDO,,,,A,,Y,,,20210727,,HP,ES,ES,Efavirenz Film Coated Tablets,Hypertension;Thrombosis,194644653,OT,,,,,,,,,194644653,1,Antiretroviral therapy
19466697,194666974,4,F,201807,20210729,20210628,20210811,EXP,,NG-CIPLA LTD.-2021NG04367,CIPLA,,,,,,Y,,,20210811,,HP,US,NG,EFAVIRENZ.,Congenital hydrocephalus;Foetal exposure during pregnancy;Hydranencephaly,194666974,CA,,,,,,,,,,,
19480478,194804781,1,I,,20210616,20210701,20210701,PER,,IN-LUPIN PHARMACEUTICALS INC.-2021-10414,LUPIN,,48,YR,,M,Y,,,20210701,,HP,IN,IN,EFAVIRENZ.,Symmetrical drug-related intertriginous and flexural exanthema,,,,,,,,,,,194804781,1,Infection prophylaxis
19480764,194807641,1,I,,20210621,20210701,20210701,EXP,,ES-AUROBINDO-AUR-APL-2021-027496,AUROBINDO,"ARAGONES EROLES, AM ET AL... RELACION ENTRE NIVELES PLASMATICOS DE EFAVIRENZ Y ALTERACIONES LIPEMICAS. REV.OFIL?ILAPHAR. 2021?31(1):64?69",,,A,,Y,,,20210701,,MD,ES,ES,EFAVIRENZ.,Acute myocardial infarction,194807641,OT,,,,,,,,,194807641,1,Antiretroviral therapy
19480837,194808371,1,I,,20210616,20210701,20210701,EXP,,GB-CIPLA LTD.-2021GB04447,CIPLA,,,,,,Y,,,20210701,,HP,US,GB,EFAVIRENZ.,Exposure during pregnancy;Premature delivery,194808371,OT,,,,,,,,,194808371,1,Antiretroviral therapy
19485086,194850861,1,I,,20210621,20210702,20210702,EXP,,ES-AUROBINDO-AUR-APL-2021-027495,AUROBINDO,,,,A,,Y,,,20210702,,HP,ES,ES,EFAVIRENZ.,Acute myocardial infarction,194850861,OT,,,,,,,,,194850861,1,Antiretroviral therapy
19488470,194884701,1,I,,20210618,20210702,20210702,PER,,BR-LUPIN PHARMACEUTICALS INC.-2021-11310,LUPIN,,42,YR,,M,Y,,,20210703,,HP,BR,BR,EFAVIRENZ.,Treatment noncompliance,,,,,,,,,,,194884701,1,Antiretroviral therapy
19493342,194933421,1,I,,20210629,20210705,20210705,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2021GSK000010,VIIV,"DESHWAL R AND  ARORA S. CLINICAL, IMMUNOLOGICAL, AND VIROLOGICAL OUTCOMES IN HIV PATIENTS ON RALTEGRAVIR?BASED SALVAGE THERAPY. INDIAN JOURNAL OF SEXUALLY TRANSMITTED DISEASES AND AIDS. 2019?40 (1):42?45",,,A,M,Y,,,20210705,,HP,IN,IN,EFAVIRENZ.,Renal tubular acidosis;Treatment failure;Virologic failure,194933421,OT,,,194933421,1,201501,,,,194933421,1,HIV infection
19493343,194933431,1,I,,20210629,20210705,20210705,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2021GSK000011,VIIV,"DESHWAL R AND  ARORA S. CLINICAL, IMMUNOLOGICAL, AND VIROLOGICAL OUTCOMES IN HIV PATIENTS ON RALTEGRAVIR?BASED SALVAGE THERAPY. INDIAN JOURNAL OF SEXUALLY TRANSMITTED DISEASES AND AIDS. 2019?40 (1):42?45",,,A,M,Y,,,20210705,,HP,IN,IN,EFAVIRENZ.,Renal tubular acidosis;Treatment failure;Virologic failure,194933431,OT,,,194933431,1,201503,,,,194933431,1,HIV infection
19493348,194933481,1,I,,20210629,20210705,20210705,EXP,,IN-GLAXOSMITHKLINE-IN2021GSK000010,GLAXOSMITHKLINE,"DESHWAL R AND  ARORA S. CLINICAL, IMMUNOLOGICAL, AND VIROLOGICAL OUTCOMES IN HIV PATIENTS ON RALTEGRAVIR?BASED SALVAGE THERAPY. INDIAN JOURNAL OF SEXUALLY TRANSMITTED DISEASES AND AIDS. 2019?40 (1):42?45",,,A,M,Y,,,20210705,,HP,IN,IN,EFAVIRENZ.,Renal tubular acidosis;Treatment failure;Virologic failure,194933481,OT,,,194933481,1,201501,,,,194933481,1,HIV infection
19493349,194933491,1,I,,20210629,20210705,20210705,EXP,,IN-GLAXOSMITHKLINE-IN2021GSK000011,GLAXOSMITHKLINE,"DESHWAL R AND  ARORA S. CLINICAL, IMMUNOLOGICAL, AND VIROLOGICAL OUTCOMES IN HIV PATIENTS ON RALTEGRAVIR?BASED SALVAGE THERAPY. INDIAN JOURNAL OF SEXUALLY TRANSMITTED DISEASES AND AIDS. 2019?40 (1):42?45",,,A,M,Y,,,20210705,,HP,IN,IN,EFAVIRENZ.,Renal tubular acidosis;Treatment failure;Virologic failure,194933491,OT,,,194933491,1,201503,,,,194933491,1,HIV infection
19503705,195037051,1,I,,20210705,20210707,20210707,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-065804,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20210707,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,195037051,OT,,,,,,,,,195037051,1,HIV infection
19503738,195037381,1,I,,20210705,20210707,20210707,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-065807,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20210707,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,195037381,OT,,,,,,,,,195037381,1,HIV infection
19506550,195065501,1,I,,20210705,20210708,20210708,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-065859,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20210708,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,195065501,OT,,,,,,,,,195065501,1,Product used for unknown indication
19507746,195077461,1,I,,20210623,20210708,20210708,EXP,,ZA-APPCO PHARMA LLC-2113602,APPCO PHARMA,,26,YR,,F,Y,,,20210708,,HP,ZA,ZA,EFAVIRENZ.,Drug ineffective;Respiratory failure,195077461,DE,,,,,,,,,195077461,1,HIV infection
19513495,195134951,1,I,,20210708,20210710,20210710,EXP,,CA-ROCHE-2866772,ROCHE,,54,YR,,M,Y,,,20210710,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,195134951,DE,,,,,,,,,195134951,1,Bipolar disorder
19513521,195135211,1,I,,20210708,20210710,20210710,EXP,,CA-ROCHE-2866837,ROCHE,,,,,M,Y,,,20210710,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,195135211,DE,,,,,,,,,195135211,1,Product used for unknown indication
19513524,195135241,1,I,,20210708,20210710,20210710,EXP,,CA-ROCHE-2866778,ROCHE,,,,,M,Y,,,20210710,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,195135241,DE,,,,,,,,,195135241,1,Product used for unknown indication
19514964,195149641,1,I,200203,20210707,20210709,20210709,EXP,,FR-GLAXOSMITHKLINE-FR2021148241,GLAXOSMITHKLINE,,56,YR,,F,Y,56,KG,20210709,,HP,FR,FR,EFAVIRENZ.,Creatinine renal clearance decreased;Glycosuria;Hypophosphataemia;Myalgia;Nephropathy toxic;Pain in extremity;Proteinuria;Renal tubular dysfunction,195149641,OT,,,195149641,1,200105,2002,,,195149641,1,HIV infection
19514965,195149651,1,I,200203,20210707,20210709,20210709,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2021148241,VIIV,,56,YR,,F,Y,56,KG,20210709,,HP,FR,FR,EFAVIRENZ.,Creatinine renal clearance decreased;Glycosuria;Hypophosphataemia;Myalgia;Nephropathy toxic;Pain in extremity;Proteinuria;Renal tubular dysfunction,195149651,OT,,,195149651,1,200105,2002,,,195149651,1,HIV infection
19518951,195189511,1,I,,20210705,20210712,20210712,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-065800,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20210712,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,195189511,OT,,,,,,,,,195189511,1,Product used for unknown indication
19519773,195197731,1,I,,20210708,20210712,20210712,EXP,,CA-ROCHE-2866834,ROCHE,,,,,M,Y,,,20210712,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,195197731,DE,,,,,,,,,195197731,1,Product used for unknown indication
19519915,195199151,1,I,,20210701,20210712,20210712,EXP,,IN-MYLANLABS-2021M1040945,MYLAN,"RUKMANGATHEN R, BRAHMANAPALLI V, THAMMISETTY D, PEMMASANI D, GALI S, ATMAKURU R. STUDY OF ADVERSE DRUG REACTIONS TO ANTIRETROVIRAL THERAPY IN A TERTIARY CARE HOSPITAL, TIRUPATI. PERSPECT?CLIN?RES 2020?11(4):158?163.",6,DEC,,F,Y,,,20210712,,HP,IN,IN,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Deafness;Hypoacusis,195199151,OT,,,,,,,,,195199151,1,HIV infection
19519945,195199451,1,I,,20210701,20210712,20210712,EXP,,IN-MYLANLABS-2021M1040950,MYLAN,"RUKMANGATHEN R, BRAHMANAPALLI V, THAMMISETTY D, PEMMASANI D, GALI S, ATMAKURU R. STUDY OF ADVERSE DRUG REACTIONS TO ANTIRETROVIRAL THERAPY IN A TERTIARY CARE HOSPITAL, TIRUPATI. PERSPECT?CLIN?RES 2020?11(4):158?163.",,,,F,Y,,,20210712,,HP,IN,IN,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Deafness;Hypoacusis,195199451,OT,,,,,,,,,195199451,1,HIV infection
19520596,195205961,1,I,,20210701,20210712,20210712,EXP,,IN-MYLANLABS-2021M1040984,MYLAN,"RUKMANGATHEN R, BRAHMANAPALLI V, THAMMISETTY D, PEMMASANI D, GALI S, ATMAKURU R. STUDY OF ADVERSE DRUG REACTIONS TO ANTIRETROVIRAL THERAPY IN A TERTIARY CARE HOSPITAL, TIRUPATI. PERSPECT?CLIN?RES 2020?11(4):158?163.",4,DEC,,F,Y,,,20210712,,HP,IN,IN,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Deafness;Hypoacusis,195205961,OT,,,,,,,,,195205961,1,HIV infection
19525161,195251611,1,I,,20210705,20210712,20210712,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-066036,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20210712,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,195251611,OT,,,,,,,,,195251611,1,Product used for unknown indication
19525999,195259991,1,I,,20210705,20210713,20210713,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-065808,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20210713,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,195259991,OT,,,,,,,,,195259991,1,Product used for unknown indication
19531557,195315572,2,F,,20210826,20210714,20210827,EXP,,CA-ROCHE-2866758,ROCHE,,,,,M,Y,,,20210827,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,195315572,HO,,,,,,,,,195315572,1,Product used for unknown indication
19538738,195387381,1,I,,20210616,20210714,20210714,PER,,US-CIPLA LTD.-2021US04456,CIPLA,,,,,,Y,,,20210714,,HP,US,US,EFAVIRENZ.,Exposure during pregnancy;No adverse event,,,,,195387381,4,2019,,,,195387381,1,Antiretroviral therapy
19539691,195396911,1,I,,20210708,20210714,20210714,EXP,,CA-ROCHE-2866762,ROCHE,,,,,M,Y,,,20210714,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,195396911,OT,,,,,,,,,195396911,1,Product used for unknown indication
19541302,195413021,1,I,,20210705,20210713,20210713,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-065836,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20210713,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Intentional product use issue,195413021,OT,,,,,,,,,195413021,1,Product used for unknown indication
19557806,195578061,1,I,,20210705,20210715,20210715,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-065832,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20210715,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,195578061,OT,,,,,,,,,195578061,1,HIV infection
19564559,195645591,1,I,,20210712,20210714,20210714,EXP,,DE-GILEAD-2021-0540451,GILEAD,"LUTZE S, RIEBE H, JUNGER M, ARNOLD A. THE COURSE OF KAPOSI^S SARCOMA, A MARKER DISEASE FOR THE INITIAL DIAGNOSIS OF AIDS, UNDER ONGOING CART. CLIN HEMORHEOL MICROCIRC.. 2020?76(2):263?277. DOI:10.3233/CH?209203",36,YR,A,M,Y,,,20210714,,HP,DE,DE,SUSTIVA,Immune reconstitution inflammatory syndrome associated Kaposi's sarcoma,195645591,OT,,,,,,,,,195645591,1,HIV infection
19565320,195653201,1,I,,20210705,20210714,20210714,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-065851,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20210714,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,195653201,OT,,,,,,,,,195653201,1,HIV infection
19566683,195666831,1,I,,20210712,20210716,20210716,EXP,,IT-MYLANLABS-2021M1042601,MYLAN,,51,YR,,,Y,,,20210716,,CN,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective,195666831,OT,,,,,,,,,195666831,1,HIV infection
19567805,195678051,1,I,,20210705,20210715,20210715,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-065793,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20210715,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,195678051,OT,,,,,,,,,195678051,1,Product used for unknown indication
19567906,195679061,1,I,,20210705,20210715,20210715,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-065846,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20210715,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,195679061,OT,,,,,,,,,195679061,1,HIV infection
19569270,195692701,1,I,,20210708,20210716,20210716,EXP,,CA-ROCHE-2866839,ROCHE,,54,YR,,M,Y,,,20210716,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,195692701,OT,,,,,,,,,195692701,1,Bipolar disorder
19574565,195745651,1,I,,20210706,20210719,20210719,EXP,,ZA-CIPLA LTD.-2021ZA04946,CIPLA,"BHAIJEE F, WAINWRIGHT H, MEINTJES G, WILKINSON RJ, TODD G, VRIES ED ET AL.. WARFARIN?INDUCED SKIN NECROSIS IN HIV?1?INFECTED PATIENTS WITH TUBERCULOSIS AND VENOUS THROMBOSIS. S AFR MED J. 2010?100 (6):372 TO 377",,,,,Y,,,20210719,,HP,ZA,ZA,EFAVIRENZ.,Anticoagulation drug level above therapeutic;Escherichia infection;Immune reconstitution inflammatory syndrome associated tuberculosis;Klebsiella infection;Sepsis syndrome;Skin necrosis;Wound infection,195745651,HO,,,,,,,,,195745651,1,Venous thrombosis
19574736,195747361,1,I,,20210712,20210719,20210719,EXP,,BR-GILEAD-2021-0540861,GILEAD,"ABTIBOL?BERNARDINO M, DE AP, DE OG, DE AT, RODRIGUES G, OTANI R, CHAVES B, RODRIGUES C, DE AA, REDIVO E, FERNANDES S, CASTILHO M, BENZECRY S, BOTTO?MENEZES C., MARTINEZ?ESPINOSA F, ALECRIM M. NEUROLOGICAL FINDINGS IN CHILDREN WITHOUT CONGENITAL MICROCEPHALY EXPOSED TO ZIKA VIRUS IN UTERO: A CASE SERIES STUDY. VIRUSES.. 2020?12(11):UNK. DOI:10.3390/V12111335",,,I,M,Y,,,20210719,,HP,BR,BR,EFAVIRENZ.,Disturbance in attention;Epilepsy;Foetal exposure during pregnancy;Irritability;Language disorder;Macrocephaly;Motor dysfunction,195747361,OT,,,,,,,,,195747361,1,HIV infection
19575096,195750961,1,I,,20210706,20210719,20210719,EXP,,ZA-CIPLA LTD.-2021ZA04947,CIPLA,"BHAIJEE F, WAINWRIGHT H, MEINTJES G, WILKINSON RJ, TODD G, DE VRIES E ET AL.. WARFARIN?INDUCED SKIN NECROSIS IN HIV?1?INFECTED PATIENTS WITH TUBERCULOSIS AND VENOUS THROMBOSIS. S AFR MED J. 2010?100 (6):372 TO 377",,,,,Y,,,20210719,,HP,ZA,ZA,EFAVIRENZ.,Acinetobacter infection;Anticoagulation drug level above therapeutic;Escherichia infection;Immune reconstitution inflammatory syndrome associated tuberculosis;Sepsis syndrome;Skin necrosis;Wound infection,195750961,DE,,,,,,,,,195750961,1,Vena cava thrombosis
19578788,195787881,1,I,,20210308,20210719,20210719,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2021061971,VIIV,,,,,M,Y,,,20210719,,HP,PH,PH,EFAVIRENZ.,Brain herniation;Dizziness;Dysmetria;Encephalitis;Headache;Hydrocephalus;Immune reconstitution inflammatory syndrome;Nausea;Neck pain;Vomiting,195787881,OT,,,,,,,,,195787881,1,HIV infection
19578796,195787961,1,I,,20210308,20210719,20210719,EXP,,PH-GLAXOSMITHKLINE-PH2021061971,GLAXOSMITHKLINE,,,,,M,Y,,,20210719,,HP,PH,PH,EFAVIRENZ.,Brain herniation;Dizziness;Dysmetria;Encephalitis;Headache;Hydrocephalus;Immune reconstitution inflammatory syndrome;Nausea;Neck pain;Vomiting,195787961,HO,,,,,,,,,195787961,1,HIV infection
19580513,195805131,1,I,20210427,20210511,20210720,20210720,EXP,,TH-SA-2021SA160377,SANOFI AVENTIS,,22,YR,A,M,Y,,,20210720,,HP,TH,TH,EFAVIRENZ.,COVID-19;Pneumonia;Pyrexia;SARS-CoV-2 test positive,195805131,HO,,,195805131,1,20210330,20210426,,,195805131,1,Latent tuberculosis
19584745,195847451,1,I,,20210712,20210720,20210720,EXP,,ID-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-069811,BRISTOL MYERS SQUIBB,"PONGBULAAN A, TRIYONO EA. GIGANTOMASTIA BILATERAL INDUCED EFAVIRENZ: A CASE REPORT. INDIAN JOURNAL OF FORENSIC MEDICINE AND TOXICOLOGY. 2021?15(3):956?60",25,YR,,F,Y,63,KG,20210720,,HP,ID,ID,EFAVIRENZ.,Breast enlargement,195847451,OT,,,,,,,,,195847451,1,HIV infection
19586522,195865221,1,I,,20090824,20210721,20210721,EXP,,ZA-AUROBINDO-AUR-APL-2009-00480,AUROBINDO,UNKNOWN ARTICLE. REACTIONS WEEKLY. 2009?30,32,YR,,F,Y,,,20210721,,MD,ZA,ZA,EFAVIRENZ.,Hepatic failure;Lactic acidosis;Maternal exposure during pregnancy;Tachypnoea;Toxicity to various agents,195865221,HO,,,195865221,1,200701,,,,195865221,1,Antiretroviral therapy
19593088,195930881,1,I,,20210719,20210722,20210722,EXP,,FR-GILEAD-2021-0541395,GILEAD,"FAURE C, CHASSERY M, OREAS R, AUDO I. DIDANOSINE?INDUCED RETINOPATHY: NEW INSIGHTS WITH LONG?TERM FOLLOW?UP. OCULAR IMMUNOLOGY + INFLAMMATION. 2021?UNK:1?8. DOI:10.1080/09273948.2021.1927117",56,YR,A,M,Y,,,20210722,,HP,FR,FR,EFAVIRENZ.,Drug interaction;Retinal toxicity,195930881,OT,,,,,,,,,195930881,1,HIV infection
19603988,196039881,1,I,,20210716,20210723,20210723,EXP,,CA-ASTRAZENECA-2021A627254,ASTRAZENECA,,54,YR,,M,Y,,,20210723,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,196039881,OT,,,,,,,,,196039881,1,Bipolar disorder
19604002,196040021,1,I,,20210715,20210723,20210723,EXP,,ES-MYLANLABS-2021M1043717,MYLAN,,40,YR,,M,Y,,,20210723,,CN,ES,ES,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone disorder;Renal failure,196040021,OT,,,,,,,,,196040021,1,HIV infection
19604124,196041241,1,I,201411,20210524,20210723,20210723,EXP,,HR-009507513-2107HRV006804,MERCK,,66,YR,,M,Y,,,20210723,,MD,HR,HR,EFAVIRENZ.,Cardiac arrest;Congenital cystic kidney disease;Hypertension;Myocardial infarction,196041241,OT,,,196041241,1,200807,200808,,,196041241,1,HIV infection
19607658,196076581,1,I,,20210719,20210726,20210726,EXP,,CA-BAUSCH-BL-2021-025924,BAUSCH AND LOMB,,54,YR,,M,Y,,,20210726,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,196076581,OT,,,,,,,,,196076581,1,Bipolar disorder
19607667,196076671,1,I,,20210719,20210726,20210726,EXP,,CA-BAUSCH-BL-2021-025896,BAUSCH AND LOMB,,,,,M,Y,,,20210726,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,196076671,OT,,,,,,,,,196076671,1,Bipolar disorder
19607676,196076761,1,I,,20210719,20210726,20210726,EXP,,CA-BAUSCH-BL-2021-025925,BAUSCH AND LOMB,,54,YR,,M,Y,,,20210726,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,196076761,OT,,,,,,,,,196076761,1,Bipolar disorder
19607677,196076771,1,I,,20210719,20210726,20210726,EXP,,CA-BAUSCH-BL-2021-025931,BAUSCH AND LOMB,,54,YR,,M,Y,,,20210726,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,196076771,OT,,,,,,,,,196076771,1,Bipolar disorder
19608296,196082961,1,I,,20210719,20210726,20210726,EXP,,CA-BAUSCH-BL-2021-025915,BAUSCH AND LOMB,,54,YR,,M,Y,,,20210726,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,196082961,OT,,,,,,,,,196082961,1,Product used for unknown indication
19608297,196082971,1,I,,20210719,20210726,20210726,EXP,,CA-BAUSCH-BL-2021-025928,BAUSCH AND LOMB,,54,YR,,M,Y,,,20210726,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,196082971,OT,,,,,,,,,196082971,1,Bipolar disorder
19608298,196082981,1,I,,20210719,20210726,20210726,EXP,,CA-BAUSCH-BL-2021-025922,BAUSCH AND LOMB,,54,YR,,M,Y,,,20210726,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,196082981,OT,,,,,,,,,196082981,1,Product used for unknown indication
19608311,196083111,1,I,,20210719,20210726,20210726,EXP,,CA-BAUSCH-BL-2021-025921,BAUSCH AND LOMB,,54,YR,,M,Y,,,20210726,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,196083111,OT,,,,,,,,,196083111,1,Bipolar disorder
19609605,196096052,2,F,,20210719,20210726,20210924,EXP,,CA-BAUSCH-BL-2021-025913,BAUSCH AND LOMB,,54,YR,,M,Y,,,20210924,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,196096052,OT,,,,,,,,,196096052,1,Bipolar disorder
19609608,196096081,1,I,,20210719,20210726,20210726,EXP,,CA-BAUSCH-BL-2021-025907,BAUSCH AND LOMB,,,,,M,Y,,,20210726,,HP,CA,CA,EFAVIRENZ.,Depression;Drug interaction,196096081,OT,,,,,,,,,196096081,1,Product used for unknown indication
19609609,196096091,1,I,,20210719,20210726,20210726,EXP,,CA-BAUSCH-BL-2021-025927,BAUSCH AND LOMB,,54,YR,,M,Y,,,20210726,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,196096091,OT,,,,,,,,,196096091,1,Bipolar disorder
19609615,196096151,1,I,,20210719,20210726,20210726,EXP,,CA-BAUSCH-BL-2021-025926,BAUSCH AND LOMB,,54,YR,,M,Y,,,20210726,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,196096151,OT,,,,,,,,,196096151,1,Bipolar disorder
19609616,196096161,1,I,,20210719,20210726,20210726,EXP,,CA-BAUSCH-BL-2021-025917,BAUSCH AND LOMB,,54,YR,,M,Y,,,20210726,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,196096161,OT,,,,,,,,,196096161,1,Product used for unknown indication
19609617,196096171,1,I,,20210719,20210726,20210726,EXP,,CA-BAUSCH-BL-2021-025923,BAUSCH AND LOMB,,54,YR,,M,Y,,,20210726,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,196096171,OT,,,,,,,,,196096171,1,Bipolar disorder
19610791,196107911,1,I,,20210712,20210726,20210726,EXP,,ZM-CMP PHARMA-2021CMP00016,CMP PHARMA,"KABENGELE C, M^HANGO H, MWEEMBA D, MALUMANI M.. A PECULIARLY CHARACTERISED CASE OF ISONIAZID?INDUCED PELLAGRA?2 DS AND A C: A CASE REPORT.. PAN AFR MED J.. 2021?39(73)",40,YR,,F,Y,,,20210726,,MD,ZM,ZM,EFAVIRENZ.,Constipation;Nicotinic acid deficiency,196107911,HO,,,,,,,,,196107911,1,Tuberculosis
19611113,196111131,1,I,,20210722,20210726,20210726,EXP,,NVSC2021IN167226,NOVARTIS,,35,YR,,F,Y,,,20210726,,HP,IN,IN,TENOFOVIR + LAMIVUDINE + EFAVIRENZ,Drug reaction with eosinophilia and systemic symptoms,196111131,OT,,,,,,,,,196111131,1,Leprosy
19611336,196113361,1,I,,20210625,20210727,20210727,PER,,GB-LUPIN PHARMACEUTICALS INC.-2021-10951,LUPIN,,,,A,M,Y,,,20210727,,CN,GB,GB,EFAVIRENZ.,Intercepted medication error;Product prescribing error,,,,,,,,,,,196113361,1,Product used for unknown indication
19617759,196177591,1,I,,20210714,20210728,20210728,EXP,,CA-AUROBINDO-AUR-APL-2021-031431,AUROBINDO,,80,YR,,M,Y,,,20210728,,HP,CA,CA,EFAVIRENZ.,Depression;Diarrhoea;Drug resistance,196177591,OT,,,,,,,,,196177591,1,HIV infection
19636915,196369151,1,I,2017,20210726,20210729,20210729,EXP,,US-GILEAD-2021-0542208,GILEAD,,,,A,M,Y,,,20210729,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hepatitis C;Sleep disorder,196369151,OT,,,,,,,,,196369151,1,HIV infection
19644144,196441441,1,I,,20210721,20210731,20210731,EXP,,FR-AUROBINDO-AUR-APL-2021-032721,AUROBINDO,,29,YR,,,Y,,,20210801,,CN,FR,FR,Efavirenz+Emtricitabine+Tenofovir Film  coated Tablets,Depression;Drug ineffective;Negative thoughts;Psychiatric symptom;Viral load increased,196441441,OT,,,196441441,1,202012,,,,196441441,1,Product used for unknown indication
19645052,196450521,1,I,201411,20210726,20210802,20210802,EXP,,HR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-073219,BRISTOL MYERS SQUIBB,,66,YR,,M,Y,,,20210802,,MD,HR,HR,EFAVIRENZ.,Cardiac arrest;Congenital cystic kidney disease;Hypertension;Myocardial infarction,196450521,OT,,,196450521,1,200807,201503,,,196450521,1,HIV infection
19646677,196466771,1,I,,20210419,20210802,20210802,EXP,,DE-GILEAD-2021-0526291,GILEAD,"RADMER S, ANDRESEN J, ANDRESEN R. DIMINISHED BONE MARROW OEDEMA AND HEALING OF INSUFFICIENCY FRACTURES IN A HIV PATIENT AFTER SWITCHING ANTIVIRAL THERAPIES. UNK. 2021?15(3):UNK. DOI:10.7860/JCDR/2020/46523.14738",64,YR,A,M,Y,,,20210802,,HP,DE,DE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone marrow oedema syndrome;Foot fracture;Renal failure,196466771,OT,,,,,,,,,196466771,1,HIV infection
19646695,196466952,2,F,,20210721,20210802,20210805,EXP,,CA-MYLANLABS-2021M1046365,MYLAN,,,,,M,Y,,,20210805,,HP,CA,CA,EFAVIRENZ.,Depression;Drug interaction,196466952,OT,,,,,,,,,196466952,1,Product used for unknown indication
19658105,196581051,1,I,,20210721,20210804,20210804,EXP,,PH-APPCO PHARMA LLC-2114628,APPCO PHARMA,,30,YR,,M,Y,,,20210804,,HP,PH,PH,EFAVIRENZ.,Condition aggravated;Encephalitis,196581051,OT,,,,,,,,,196581051,1,Product used for unknown indication
19673653,196736532,2,F,20080115,20210806,20210809,20210812,EXP,,US-ABBVIE-21K-163-4027153-00,ABBVIE,,47,YR,,M,Y,49.89,KG,20210812,,LW,US,US,SUSTIVA,Bone density decreased;Bone loss;Chronic kidney disease;Economic problem;Emotional distress;Femoral neck fracture;Haematuria;Hip arthroplasty;Illness;Nausea;Osteoarthritis;Osteonecrosis;Osteopenia;Osteoporosis;Pain;Proteinuria;Renal failure;Rib fracture;Stress fracture;Tooth loss,196736532,OT,,,196736532,3,200406,2007,,,196736532,1,Product used for unknown indication
19674222,196742221,1,I,,20210728,20210809,20210809,EXP,,CA-APOTEX-2021AP028482,APOTEX,,54,YR,,M,Y,,,20210809,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,196742221,OT,,,,,,,,,196742221,1,HIV infection
19674465,196744651,1,I,,20201228,20210809,20210809,EXP,,TH-ALKEM LABORATORIES LIMITED-TH-ALKEM-2020-09459,ALKEM,"KAEWPOOWAT Q, CHAIWARITH R, YASRI S, WORASILCHAI N, ET AL. DRUG?DRUG INTERACTION BETWEEN ITRACONAZOLE CAPSULE AND EFAVIRENZ IN ADULTS WITH HIV FOR TALAROMYCOSIS TREATMENT. J ANTIMICROB CHEMOTHER. 2020?UNK:1?5",,,,,Y,,,20210809,,HP,TH,TH,EFAVIRENZ.,Drug interaction,,,,,,,,,,,196744651,1,Fungal infection
19674466,196744661,1,I,,20201228,20210809,20210809,EXP,,TH-ALKEM LABORATORIES LIMITED-TH-ALKEM-2020-09461,ALKEM,"KAEWPOOWAT Q, CHAIWARITH R, YASRI S, WORASILCHAI N, ET AL. DRUG?DRUG INTERACTION BETWEEN ITRACONAZOLE CAPSULE AND EFAVIRENZ IN ADULTS WITH HIV FOR TALAROMYCOSIS TREATMENT. J ANTIMICROB CHEMOTHER. 2020?UNK:1?5",,,,,Y,,,20210809,,HP,TH,TH,EFAVIRENZ.,Drug interaction,,,,,,,,,,,196744661,1,Fungal infection
19674472,196744721,1,I,,20201228,20210809,20210809,EXP,,TH-ALKEM LABORATORIES LIMITED-TH-ALKEM-2020-09462,ALKEM,"KAEWPOOWAT Q, CHAIWARITH R, YASRI S, WORASILCHAI N, ET AL. DRUG?DRUG INTERACTION BETWEEN ITRACONAZOLE CAPSULE AND EFAVIRENZ IN ADULTS WITH HIV FOR TALAROMYCOSIS TREATMENT. J ANTIMICROB CHEMOTHER. 2020?UNK:1?5",,,,,Y,,,20210809,,HP,TH,TH,EFAVIRENZ.,Drug interaction,,,,,,,,,,,196744721,1,Fungal infection
19674473,196744731,1,I,,20201228,20210809,20210809,EXP,,TH-ALKEM LABORATORIES LIMITED-TH-ALKEM-2020-09460,ALKEM,"KAEWPOOWAT Q, CHAIWARITH R, YASRI S, WORASILCHAI N, ET AL. DRUG?DRUG INTERACTION BETWEEN ITRACONAZOLE CAPSULE AND EFAVIRENZ IN ADULTS WITH HIV FOR TALAROMYCOSIS TREATMENT. J ANTIMICROB CHEMOTHER. 2020?UNK:1?5",,,,,Y,,,20210809,,HP,TH,TH,EFAVIRENZ.,Drug interaction,,,,,,,,,,,196744731,1,Fungal infection
19674493,196744931,1,I,,20210803,20210809,20210809,EXP,,CA-ROCHE-2884574,ROCHE,,54,YR,,M,Y,,,20210809,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,196744931,OT,,,,,,,,,196744931,1,Bipolar disorder
19674634,196746341,1,I,,20210803,20210809,20210809,EXP,,CA-ROCHE-2883921,ROCHE,,54,YR,,M,Y,,,20210809,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,196746341,OT,,,,,,,,,196746341,1,Bipolar disorder
19675577,196755771,1,I,,20210728,20210809,20210809,EXP,,CA-APOTEX-2021AP028405,APOTEX,,54,YR,,M,Y,,,20210809,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,196755771,OT,,,,,,,,,196755771,1,Product used for unknown indication
19676829,196768291,1,I,,20210804,20210810,20210810,EXP,,CA-ROCHE-2884400,ROCHE,,,,,M,Y,,,20210810,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,196768291,OT,,,,,,,,,196768291,1,Product used for unknown indication
19676882,196768821,1,I,,20210805,20210810,20210810,EXP,,CA-ROCHE-2885813,ROCHE,,54,YR,,M,Y,,,20210810,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,196768821,OT,,,,,,,,,196768821,1,Product used for unknown indication
19680350,196803501,1,I,,20210809,20210810,20210810,EXP,,US-GILEAD-2021-0543607,GILEAD,,,,A,M,Y,,,20210810,,HP,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hypovolaemic shock;Intentional dose omission,196803501,OT,,,,,,,,,196803501,1,HIV infection
19685340,196853401,1,I,,20210809,20210811,20210811,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-079067,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20210811,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,196853401,DE,,,,,,,,,196853401,1,Product used for unknown indication
19685653,196856531,1,I,,20210727,20210811,20210811,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-307392,RANBAXY,"HAYES AR, SMITH K, LIU M, JENKINSON S, GROSSMAN AB, YOULE M, ET AL. TREATING NEUROENDOCRINE NEOPLASMS IN THE SETTING OF HIV INFECTION. TRANSL SCI RARE DIS. 2020?5(3):143?159",54,YR,,M,Y,,,20210811,,HP,GB,GB,EFAVIRENZ.,Disease progression,196856531,OT,,,,,,,,,196856531,1,Neuroendocrine tumour of the lung
19687813,196878131,1,I,,20210809,20210811,20210811,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-079043,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20210811,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,196878131,OT,,,,,,,,,196878131,1,HIV infection
19688961,196889611,1,I,,20210730,20210812,20210812,EXP,,US-CIPLA LTD.-2021US05449,CIPLA,,,,,,Y,,,20210812,,HP,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR,Herpes zoster;Neutropenia,196889611,OT,,,,,,,,,196889611,1,Lymphoma AIDS related
19689295,196892951,1,I,,20210803,20210812,20210812,EXP,,CA-APOTEX-2021AP029842,APOTEX,,54,YR,,M,Y,,,20210812,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,196892951,OT,,,,,,,,,196892951,1,Bipolar disorder
19689296,196892961,1,I,,20210803,20210812,20210812,EXP,,CA-APOTEX-2021AP029841,APOTEX,,54,YR,,M,Y,,,20210812,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,196892961,OT,,,,,,,,,196892961,1,Bipolar disorder
19689473,196894731,1,I,,20210805,20210811,20210811,EXP,,AU-GILEAD-2021-0543435,GILEAD,,,,,F,Y,,,20210811,,CN,AU,AU,EFAVIRENZ.,Behaviour disorder;Central nervous system inflammation;Cerebellar syndrome;Chorea;Confusional state;Disorientation;Dysarthria;Dysdiadochokinesis;Gait disturbance;HIV-associated neurocognitive disorder;Hypophagia;Loss of personal independence in daily activities;Magnetic resonance imaging head abnormal;Meningitis viral;Meningoencephalitis viral;Parainfluenzae virus infection;Pathogen resistance;Rhinitis;Treatment noncompliance;Viral mutation identified,196894731,OT,,,,,,,,,196894731,1,Product used for unknown indication
19690393,196903931,1,I,,20210809,20210812,20210812,EXP,,US-SNT-000173,SINOTHERAPEUTICS,,53,YR,A,F,Y,,,20210812,,HP,US,US,EFAVIRENZ.,Debridement;Diabetic nephropathy;Disease recurrence;Glomerulosclerosis;Product use in unapproved indication;Renal impairment;Vascular hyalinosis,196903931,OT,,,,,,,,,196903931,1,Product use in unapproved indication
19691781,196917811,1,I,,20210809,20210812,20210812,EXP,,CA-ASTRAZENECA-2021A673857,ASTRAZENECA,,54,YR,,M,Y,,,20210812,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,196917811,OT,,,,,,,,,196917811,1,Bipolar disorder
19694004,196940041,1,I,,20210803,20210813,20210813,EXP,,CA-ROCHE-2883915,ROCHE,,54,YR,,M,Y,,,20210813,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,196940041,OT,,,,,,,,,196940041,1,Bipolar disorder
19694708,196947081,1,I,,20210809,20210812,20210812,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-079020,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20210812,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,196947081,OT,,,,,,,,,196947081,1,Product used for unknown indication
19694709,196947091,1,I,,20210809,20210812,20210812,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-078979,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20210812,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,196947091,OT,,,,,,,,,196947091,1,Product used for unknown indication
19698158,196981581,1,I,,20210729,20210813,20210813,EXP,,CA-ALVOGEN-2021-ALVOGEN-117297,ALVOGEN,,54,YR,,M,Y,,,20210813,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,196981581,OT,,,,,,,,,196981581,1,Bipolar disorder
19698810,196988101,1,I,,20210803,20210813,20210813,EXP,,CA-APOTEX-2021AP029843,APOTEX,,54,YR,,M,Y,,,20210813,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,196988101,OT,,,,,,,,,196988101,1,Bipolar disorder
19700181,197001811,1,I,,20210803,20210813,20210813,EXP,,CA-ROCHE-2883942,ROCHE,,54,YR,,M,Y,,,20210813,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,197001811,OT,,,,,,,,,197001811,1,Bipolar disorder
19701763,197017631,1,I,,20210803,20210813,20210813,EXP,,CA-ROCHE-2884211,ROCHE,,54,YR,,M,Y,,,20210813,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,197017631,OT,,,,,,,,,197017631,1,Bipolar disorder
19701796,197017961,1,I,,20210803,20210813,20210813,EXP,,CA-ROCHE-2884622,ROCHE,,54,YR,,M,Y,,,20210813,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,197017961,OT,,,,,,,,,197017961,1,Product used for unknown indication
19701797,197017971,1,I,,20210803,20210813,20210813,EXP,,CA-ROCHE-2884472,ROCHE,,54,YR,,M,Y,,,20210813,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,197017971,OT,,,,,,,,,197017971,1,Bipolar disorder
19702158,197021581,1,I,,20210804,20210813,20210813,EXP,,CA-ROCHE-2885595,ROCHE,,54,YR,,M,Y,,,20210814,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,197021581,OT,,,,,,,,,197021581,1,Bipolar disorder
19705246,197052461,1,I,,20210809,20210816,20210816,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-079002,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20210816,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,197052461,HO,,,,,,,,,197052461,1,Product used for unknown indication
19706428,197064281,1,I,,20210803,20210817,20210817,EXP,,CA-ALVOGEN-2021-ALVOGEN-117313,ALVOGEN,,54,YR,,M,Y,,,20210817,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,197064281,OT,,,,,,,,,197064281,1,Product used for unknown indication
19707415,197074151,1,I,,20210809,20210817,20210817,EXP,,CA-ASTRAZENECA-2021A674396,ASTRAZENECA,,54,YR,,M,Y,,,20210817,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,197074151,OT,,,,,,,,,197074151,1,Bipolar disorder
19707503,197075031,1,I,,20210809,20210817,20210817,EXP,,TH-MYLANLABS-2021M1052686,MYLAN,,45,YR,,F,Y,,,20210817,,HP,TH,TH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Immune reconstitution inflammatory syndrome;Paradoxical drug reaction,197075031,HO,,,,,,,,,197075031,1,HIV infection
19709671,197096711,1,I,,20210809,20210817,20210817,EXP,,CA-ASTRAZENECA-2021A674114,ASTRAZENECA,,,,,M,Y,,,20210817,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,197096711,HO,,,,,,,,,197096711,2,Product used for unknown indication
19709900,197099001,1,I,,20210802,20210816,20210816,EXP,,US-VIIV HEALTHCARE LIMITED-US2021GSK164447,VIIV,"GALLARDO CM, WANG S, MONTIEL?GARCIA DJ, LITTLE SJ, SMITH DM, ROUTH AL ET AL. MRHAMER YIELDS HIGHLY ACCURATE SINGLE MOLECULE VIRAL SEQUENCES ENABLING ANALYSIS OF INTRA?HOST EVOLUTION. NUCLEIC ACIDS RESEARCH. 2021?49 (12)",,,,,Y,,,20210816,,HP,US,US,EFAVIRENZ.,Blood HIV RNA increased;Pathogen resistance;Viral mutation identified;Virologic failure,197099001,OT,,,,,,,,,197099001,1,HIV infection
19709901,197099011,1,I,,20210802,20210816,20210816,EXP,,US-GLAXOSMITHKLINE-US2021GSK164447,GLAXOSMITHKLINE,"GALLARDO CM, WANG S, MONTIEL?GARCIA DJ, LITTLE SJ, SMITH DM, ROUTH AL ET AL. MRHAMER YIELDS HIGHLY ACCURATE SINGLE MOLECULE VIRAL SEQUENCES ENABLING ANALYSIS OF INTRA?HOST EVOLUTION. NUCLEIC ACIDS RESEARCH. 2021?49 (12)",,,,,Y,,,20210816,,HP,US,US,EFAVIRENZ.,Blood HIV RNA increased;Pathogen resistance;Viral mutation identified;Virologic failure,197099011,OT,,,,,,,,,197099011,1,HIV infection
19710219,197102191,1,I,,20210809,20210817,20210817,EXP,,CA-ASTRAZENECA-2021A674272,ASTRAZENECA,,54,YR,,M,Y,,,20210817,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,197102191,OT,,,,,,,,,197102191,1,Bipolar disorder
19711338,197113383,3,F,,20210906,20210817,20210910,EXP,,DE-MYLANLABS-2021M1052063,MYLAN,,57,YR,,M,Y,,,20210910,,CN,DE,DE,EFAVIRENZ.,Drug resistance,197113383,OT,,,,,,,,,197113383,1,HIV infection
19711891,197118911,1,I,,20210803,20210816,20210816,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-081211,BRISTOL MYERS SQUIBB,"FAURE C, CHASSERY M, ORES R, AUDO I. DIDANOSINE?INDUCED RETINOPATHY: NEW INSIGHTS WITH LONG?TERM FOLLOW?UP. OCULAR IMMUNOLOGY AND INFLAMMATION. 2021?1?8",56,YR,,M,Y,,,20210816,,MD,FR,FR,EFAVIRENZ.,Retinopathy,197118911,OT,,,,,,,,,197118911,1,HIV infection
19711977,197119771,1,I,,20210809,20210816,20210816,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-079033,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20210816,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,197119771,OT,,,,,,,,,197119771,1,HIV infection
19713268,197132681,1,I,,20210809,20210816,20210816,EXP,,CA-ASTRAZENECA-2021A674296,ASTRAZENECA,,,,,M,Y,,,20210817,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,197132681,HO,,,,,,,,,197132681,1,Product used for unknown indication
19718231,197182311,1,I,,20210809,20210819,20210819,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-078977,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20210819,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,197182311,OT,,,,,,,,,197182311,1,Product used for unknown indication
19719432,197194321,1,I,,20210526,20210819,20210819,EXP,,DE-AUROBINDO-AUR-APL-2021-023669,AUROBINDO,,64,YR,,M,Y,,,20210819,,MD,DE,DE,Efavirenz+Emtricitabine+Tenofovir Film  coated Tablets,Bone marrow oedema syndrome;Drug ineffective;Foot fracture;Product use issue;Renal failure,197194321,OT,,,,,,,,,197194321,1,Bone marrow oedema
19722738,197227381,1,I,,20210812,20210819,20210819,EXP,,ES-VIIV HEALTHCARE LIMITED-EC2021GSK174665,VIIV,"GARCIA?BOYANO M, VEGA W, PRIETO L, CHAVEZ?SOLORZANO N, MONTIEL DS, MINO?LEON G. PROGRESSIVE DISSEMINATED HISTOPLASMOSIS IN CHILDREN LIVING WITH HIV: A CASE SERIES STUDY. EUROPEAN JOURNAL OF PEDIATRICS. 2021?180 (6):1923?1931",,,C,M,Y,,,20210819,,MD,ES,EC,EFAVIRENZ.,Diarrhoea;Disease recurrence;Hepatomegaly;Histoplasmosis disseminated;Lymphadenopathy;Pyrexia;Splenomegaly;Treatment noncompliance;Virologic failure,197227381,DE,,,197227381,1,2015,,,,197227381,1,HIV infection
19722740,197227401,1,I,,20210812,20210819,20210819,EXP,,ES-GLAXOSMITHKLINE-EC2021GSK174665,GLAXOSMITHKLINE,"GARCIA?BOYANO M, VEGA W, PRIETO L, CHAVEZ?SOLORZANO N, MONTIEL DS, MINO?LEON G. PROGRESSIVE DISSEMINATED HISTOPLASMOSIS IN CHILDREN LIVING WITH HIV: A CASE SERIES STUDY. EUROPEAN JOURNAL OF PEDIATRICS. 2021?180 (6):1923?1931",,,C,M,Y,,,20210819,,MD,ES,EC,EFAVIRENZ.,Diarrhoea;Disease recurrence;Hepatomegaly;Histoplasmosis disseminated;Lymphadenopathy;Pyrexia;Splenomegaly;Treatment noncompliance;Virologic failure,197227401,OT,,,197227401,1,2015,,,,197227401,1,HIV infection
19722912,197229122,2,F,,20210901,20210820,20210914,EXP,,IT-AUROBINDO-AUR-APL-2021-035128,AUROBINDO,,56,YR,,M,Y,,,20210914,,HP,IT,IT,EFAVIRENZ.,Herpes virus infection;Pancytopenia;Pneumonia bacterial;Product use in unapproved indication,197229122,OT,,,,,,,,,197229122,1,Graft versus host disease
19731168,197311681,1,I,,20210818,20210821,20210821,EXP,,CA-ROCHE-2894795,ROCHE,,54,YR,,M,Y,,,20210821,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,197311681,OT,,,,,,,,,197311681,1,Bipolar disorder
19733393,197333931,1,I,,20210818,20210823,20210823,EXP,,CA-ROCHE-2894586,ROCHE,,54,YR,,M,Y,,,20210823,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,197333931,OT,,,,,,,,,197333931,1,Bipolar disorder
19734669,197346691,1,I,,20210303,20210824,20210824,EXP,,CA-ROCHE-2782429,ROCHE,,44,YR,,M,Y,,,20210824,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,197346691,HO,,,,,,,,,197346691,1,Depression
19738098,197380981,1,I,,20210818,20210824,20210824,EXP,,CA-ROCHE-2894768,ROCHE,,,,,M,Y,,,20210824,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,197380981,DE,,,,,,,,,197380981,1,Product used for unknown indication
19739652,197396521,1,I,,20210817,20210824,20210824,EXP,,GH-MYLANLABS-2021M1054459,MYLAN,"KUMBENI MT, APANGA PA, AYAMGA EA. NEXPLANON FAILURE IN A WOMAN WITH HIV INFECTION IN RURAL GHANA: A CASE REPORT. CLIN?CASE?REP 2020?8(12):2369?2372.",37,YR,,F,Y,68,KG,20210824,,HP,GH,GH,EFAVIRENZ.,Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy on contraceptive,197396521,OT,,,197396521,1,2014,,,,197396521,1,HIV infection
19739667,197396671,1,I,,20210816,20210824,20210824,EXP,,CA-TEVA-2021-CA-1944179,TEVA,,27,YR,A,M,Y,,,20210824,,HP,CA,CA,TEVA EFAVIRENZ / EMTRICITABINE / TENOFOVIR,Dizziness;Feeling abnormal;Loss of personal independence in daily activities;Neurotoxicity,197396671,OT,,,,,,,,,,,
19740419,197404191,1,I,,20210815,20210824,20210824,EXP,,GB-TEVA-2021-GB-1944045,TEVA,,60,YR,A,M,Y,,,20210824,,CN,GB,GB,EFAVIRENZ.,Viral load increased,197404191,OT,,,197404191,3,202104,,,,197404191,1,Asthma
19744986,197449861,1,I,,20210820,20210825,20210825,EXP,,CA-009507513-2108CAN005807,MERCK,,54,YR,,M,Y,,,20210825,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,197449861,DE,,,,,,,,,197449861,1,Product used for unknown indication
19746601,197466011,1,I,,20210815,20210825,20210825,EXP,,NVSC2021GB185232,NOVARTIS,,60,YR,,M,Y,,,20210825,,HP,GB,GB,EFAVIRENZ.,Viral load increased,197466011,OT,,,197466011,4,2019,,,,197466011,1,Asthma
19748411,197484111,1,I,,20210825,20210826,20210826,EXP,,CA-ROCHE-2898555,ROCHE,,,,,M,Y,,,20210826,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,197484111,HO,,,,,,,,,197484111,1,Product used for unknown indication
19748412,197484121,1,I,,20210825,20210826,20210826,EXP,,CA-ROCHE-2898001,ROCHE,,54,YR,,M,Y,,,20210826,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,197484121,OT,,,,,,,,,197484121,1,Bipolar disorder
19748805,197488051,1,I,,20210815,20210826,20210826,EXP,,GB-AUROBINDO-AUR-APL-2021-036140,AUROBINDO,,60,YR,,M,Y,,,20210826,,CN,GB,GB,EFAVIRENZ.,Viral load increased,197488051,OT,,,197488051,3,202104,,,,197488051,1,Asthma
19749484,197494841,1,I,20181214,20210816,20210826,20210826,EXP,,CZ-MYLANLABS-2021M1053292,MYLAN,,53,YR,,M,Y,,,20210826,,CN,CZ,CZ,EFAVIRENZ.,Drug ineffective;Dysuria;HIV infection;Immunodeficiency;Kaposi's sarcoma;Laboratory test abnormal;Lymphoedema;Multiple-drug resistance;Neoplasm progression;Pancytopenia;Pyrexia;Skin lesion;Toxicity to various agents;Urinary tract infection;Virologic failure,197494841,OT,,,197494841,1,2021,19990322,,,197494841,1,Kaposi's sarcoma
19752086,197520861,1,I,,20210823,20210827,20210827,EXP,,CA-BAUSCH-BL-2021-028927,BAUSCH AND LOMB,,,,,M,Y,,,20210827,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,197520861,HO,,,,,,,,,197520861,1,Product used for unknown indication
19752645,197526451,1,I,,20210826,20210827,20210827,EXP,,CA-ROCHE-2899547,ROCHE,,,,A,M,Y,,,20210827,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,197526451,OT,,,,,,,,,197526451,1,Bipolar disorder
19752800,197528001,1,I,,20210823,20210827,20210827,EXP,,CA-BAUSCH-BL-2021-028933,BAUSCH AND LOMB,,,,,M,Y,,,20210827,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,197528001,DE,,,,,,,,,197528001,1,Product used for unknown indication
19752801,197528011,1,I,,20210823,20210827,20210827,EXP,,CA-BAUSCH-BL-2021-028939,BAUSCH AND LOMB,,54,YR,,M,Y,,,20210827,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,197528011,OT,,,,,,,,,197528011,1,Bipolar disorder
19752813,197528131,1,I,,20210823,20210827,20210827,EXP,,CA-BAUSCH-BL-2021-028931,BAUSCH AND LOMB,,54,YR,,M,Y,,,20210827,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,197528131,OT,,,,,,,,,197528131,1,Bipolar disorder
19752814,197528141,1,I,,20210823,20210827,20210827,EXP,,CA-BAUSCH-BL-2021-028935,BAUSCH AND LOMB,,54,YR,,M,Y,,,20210827,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,197528141,OT,,,,,,,,,197528141,1,Bipolar disorder
19755155,197551551,1,I,,20210815,20210827,20210827,EXP,GB-MHRA-ADR 25788706,GB-ACCORD-236528,ACCORD,,60,YR,,M,Y,,,20210827,,CN,GB,GB,EFAVIRENZ.,Off label use;Viral load increased,197551551,OT,,,197551551,3,202104,,,,197551551,1,Asthma
19756401,197564011,1,I,,20210816,20210827,20210827,EXP,,GB-MSNLABS-2021MSNSPO00345,MSN LABORATORIES,,,,,,Y,,,20210827,,CN,GB,GB,EFAVIRENZ.,Viral load increased,197564011,OT,,,197564011,4,2019,,,,197564011,1,Asthma
19759214,197592141,1,I,,20210820,20210829,20210829,EXP,,CA-009507513-2108CAN006022,MERCK,,54,YR,,M,Y,,,20210829,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,197592141,OT,,,,,,,,,197592141,1,Product used for unknown indication
19759220,197592201,1,I,,20210820,20210829,20210829,EXP,,CA-009507513-2108CAN006021,MERCK,,,,,M,Y,,,20210829,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,197592201,HO,,,,,,,,,197592201,1,Product used for unknown indication
19759699,197596991,1,I,,20210817,20210830,20210830,EXP,,CA-AUROBINDO-AUR-APL-2021-036143,AUROBINDO,,32,YR,,M,Y,,,20210830,,HP,CA,CA,EFAVIRENZ.,Genotype drug resistance test positive;Therapeutic product effect incomplete,197596991,OT,,,,,,,,,197596991,1,HIV infection
19760337,197603371,1,I,,20210823,20210830,20210830,EXP,,CA-BAUSCH-BL-2021-028940,BAUSCH AND LOMB,,54,YR,,M,Y,,,20210830,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,197603371,OT,,,,,,,,,197603371,1,Bipolar disorder
19760341,197603411,1,I,,20210823,20210830,20210830,EXP,,CA-BAUSCH-BL-2021-028952,BAUSCH AND LOMB,,54,YR,,M,Y,,,20210830,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,197603411,OT,,,,,,,,,197603411,1,Bipolar disorder
19761315,197613151,1,I,,20210816,20210830,20210830,EXP,,ID-AUROBINDO-AUR-APL-2021-036283,AUROBINDO,,25,YR,,F,Y,63,KG,20210830,,HP,ID,ID,EFAVIRENZ.,Back pain;Breast enlargement;Breast pain,197613151,OT,,,,,,,,,197613151,1,HIV infection
19762415,197624151,1,I,,20210815,20210827,20210827,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-081286,BRISTOL MYERS SQUIBB,,60,YR,,M,Y,,,20210827,,MD,GB,GB,EFAVIRENZ.,Viral load increased,197624151,OT,,,197624151,3,202104,,,,197624151,1,HIV infection
19763600,197636001,1,I,,20210823,20210830,20210830,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021GSK182789,VIIV,,54,YR,,M,Y,,,20210830,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,197636001,OT,,,,,,,,,197636001,1,Bipolar disorder
19763624,197636241,1,I,,20210823,20210830,20210830,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK182789,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20210830,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,197636241,OT,,,,,,,,,197636241,1,Bipolar disorder
19764830,197648301,1,I,,20210816,20210831,20210831,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-309484,RANBAXY,,60,YR,,M,Y,,,20210831,,HP,GB,GB,EFAVIRENZ.,Viral load increased,197648301,OT,,,197648301,3,202104,,,,197648301,1,Asthma
19764890,197648901,1,I,,20210815,20210830,20210830,EXP,,GB-MYLANLABS-2021M1052871,MYLAN,,60,YR,,M,Y,,,20210830,,CN,GB,GB,EFAVIRENZ.,Off label use;Viral load increased,197648901,OT,,,197648901,3,202104,,,,197648901,1,Asthma
19766211,197662111,1,I,,20210817,20210831,20210831,PER,,GH-LUPIN PHARMACEUTICALS INC.-2021-15823,LUPIN,,37,YR,,F,Y,68,KG,20210831,,HP,GH,GH,EFAVIRENZ.,Exposure during pregnancy,,,,,197662111,1,2014,,,,197662111,1,HIV infection
19766898,197668981,1,I,,,20210830,20210830,DIR,,,FDA-CTU,,,,,M,N,,,20210830,N,CN,US,US,SUSTIVA,Aggression;Agitation;Anger;Product use complaint,,,197668981,CSM,,,,,,,,,
19772333,197723331,1,I,,20210826,20210901,20210901,EXP,,CA-ROCHE-2899569,ROCHE,,54,YR,,M,Y,,,20210901,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,197723331,OT,,,,,,,,,197723331,1,Bipolar disorder
19775312,197753121,1,I,,20210823,20210901,20210901,EXP,,CA-TEVA-2021-CA-1947158,TEVA,,54,YR,A,M,Y,,,20210901,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,197753121,OT,,,,,,,,,197753121,1,HIV infection
19777664,197776641,1,I,,20190603,20210902,20210902,EXP,,IN-GILEAD-2021-0546329,GILEAD,"DESHWAL R, ARORA S. CLINICAL, IMMUNOLOGICAL, AND VIROLOGICAL OUTCOMES IN HIV PATIENTS ON RALTEGRAVIR?BASED SALVAGE THERAPY. INDIAN J SEX TRANSM DIS AIDS.. 2019?40 (1):42?45. DOI:10.4103/IJSTD.IJSTD_23_18",55,YR,A,M,Y,,,20210902,,MD,IN,IN,EFAVIRENZ.,Drug ineffective;Renal tubular acidosis,197776641,OT,,,197776641,1,201501,,,,197776641,1,HIV infection
19777748,197777481,1,I,,20210818,20210902,20210902,EXP,,CA-ALVOGEN-2021-ALVOGEN-117410,ALVOGEN,,54,YR,,M,Y,,,20210902,,HP,CA,CA,EFAVIRENZ.,Depression;Drug interaction,197777481,OT,,,,,,,,,197777481,1,Bipolar disorder
19777815,197778151,1,I,,20190603,20210902,20210902,EXP,,IN-GILEAD-2021-0546330,GILEAD,"DESHWAL R, ARORA S. CLINICAL, IMMUNOLOGICAL, AND VIROLOGICAL OUTCOMES IN HIV PATIENTS ON RALTEGRAVIR?BASED SALVAGE THERAPY.. INDIAN J SEX TRANSM DIS AIDS.. 2019?40(1):42?45. DOI:10.4103/IJSTD.IJSTD_23_18",56,YR,A,M,Y,,,20210902,,MD,IN,IN,EFAVIRENZ.,Drug ineffective;Renal tubular acidosis,197778151,OT,,,197778151,1,201503,,,,197778151,1,HIV infection
19779111,197791111,1,I,,20210823,20210902,20210902,EXP,,CA-TEVA-2021-CA-1947077,TEVA,,54,YR,A,M,Y,,,20210902,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,197791111,OT,,,,,,,,,197791111,1,HIV infection
19779968,197799681,1,I,,20210830,20210902,20210902,EXP,,US-GILEAD-2021-0546565,GILEAD,,42,YR,A,M,Y,,,20210902,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Infection;Pain;Renal disorder;Sleep terror;Tachyphrenia;Transfusion,197799681,OT,,,197799681,1,201309,201411,,,197799681,1,HIV infection
19781509,197815092,2,F,,20210902,20210902,20210909,EXP,,SE-MYLANLABS-2021M1057698,MYLAN,"TYRBERG E., EDEN A., ERIKSEN J., NILSSON S., TREUTIGER CJ., THALME A, ET AL.. HIGHER PLASMA DRUG LEVELS IN ELDERLY PEOPLE LIVING WITH HIV TREATED WITH DARUNAVIR. PLOS ONE. 2021?16(2)",70,YR,,M,Y,75,KG,20210909,,HP,SE,SE,EFAVIRENZ.,Diabetes mellitus;Fat redistribution;Labelled drug-drug interaction issue;Sensory loss,197815092,OT,,,,,,,,,197815092,1,HIV infection
19781519,197815191,1,I,,20210830,20210902,20210902,EXP,,SE-MYLANLABS-2021M1057927,MYLAN,"TYRBERG E, EDEN A, ERIKSEN J, NILSSON S, TREUTIGER CJ, THALME A, ET AL... HIGHER PLASMA DRUG LEVELS IN ELDERLY PEOPLE LIVING WITH HIV TREATED WITH DARUNAVIR.. PLOS ONE. 2021?16 (2)",36,YR,,M,Y,79,KG,20210902,,HP,SE,SE,EFAVIRENZ.,Abnormal dreams;Coma;Erectile dysfunction,197815191,OT,,,,,,,,,197815191,1,HIV infection
19786994,197869941,1,I,2012,20210823,20210903,20210903,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-084646,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20210903,,LW,US,US,SUSTIVA,Arthralgia;Arthropathy;Bone density abnormal;Bone density decreased;Multiple fractures;Musculoskeletal discomfort;Osteonecrosis;Osteoporosis;Tooth fracture;Tooth loss,197869941,OT,,,197869941,2,200912,2019,,,197869941,1,HIV infection
19798021,197980211,1,I,,20210830,20210907,20210907,EXP,,CA-TEVA-2021-CA-1950127,TEVA,,54,YR,A,M,Y,,,20210907,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,197980211,OT,,,,,,,,,197980211,1,HIV infection
19798119,197981191,1,I,,20210830,20210907,20210907,EXP,,CA-TEVA-2021-CA-1950195,TEVA,,54,YR,A,M,Y,,,20210907,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,197981191,OT,,,,,,,,,197981191,1,HIV infection
19798542,197985421,1,I,,20210830,20210907,20210907,EXP,,CA-TEVA-2021-CA-1950131,TEVA,,,,,M,Y,,,20210907,,HP,CA,CA,EFAVIRENZ.,Depression;Drug interaction,197985421,OT,,,,,,,,,197985421,1,Product used for unknown indication
19798920,197989201,1,I,,20210823,20210907,20210907,EXP,,CA-ALVOGEN-2021-ALVOGEN-117423,ALVOGEN,,,,,M,Y,,,20210907,,HP,CA,CA,EFAVIRENZ.,Depression;Drug interaction,197989201,HO,,,,,,,,,197989201,1,Product used for unknown indication
19799027,197990271,1,I,,20210823,20210907,20210907,EXP,,CA-ALVOGEN-2021-ALVOGEN-117425,ALVOGEN,,,,,M,Y,,,20210907,,HP,CA,CA,EFAVIRENZ.,Depression;Drug interaction,197990271,HO,,,,,,,,,197990271,1,Product used for unknown indication
19799111,197991111,1,I,,20210823,20210907,20210907,EXP,,CA-ALVOGEN-2021-ALVOGEN-117424,ALVOGEN,,54,YR,,M,Y,,,20210907,,HP,CA,CA,EFAVIRENZ.,Depression;Drug interaction;Loss of personal independence in daily activities,197991111,OT,,,,,,,,,197991111,1,Bipolar disorder
19799530,197995301,1,I,,20210831,20210907,20210907,EXP,,IT-MYLANLABS-2021M1058128,MYLAN,,31,YR,,F,Y,,,20210907,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL,Drug ineffective;Virologic failure,197995301,OT,,,,,,,,,197995301,1,HIV infection
19802607,198026071,1,I,,20210830,20210908,20210908,EXP,,CA-TEVA-2021-CA-1950206,TEVA,,54,YR,A,M,Y,,,20210908,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,198026071,OT,,,,,,,,,198026071,1,HIV infection
19802608,198026081,1,I,,20210830,20210908,20210908,EXP,,CA-TEVA-2021-CA-1950198,TEVA,,54,YR,A,M,Y,,,20210908,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,198026081,OT,,,,,,,,,198026081,1,Bipolar disorder
19802638,198026381,1,I,,20210830,20210908,20210908,EXP,,CA-TEVA-2021-CA-1950227,TEVA,,54,YR,A,M,Y,,,20210908,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,198026381,OT,,,,,,,,,198026381,1,Product used for unknown indication
19802639,198026391,1,I,,20210830,20210908,20210908,EXP,,CA-TEVA-2021-CA-1950225,TEVA,,54,YR,A,M,Y,,,20210908,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,198026391,OT,,,,,,,,,198026391,1,Product used for unknown indication
19802646,198026461,1,I,,20210830,20210908,20210908,EXP,,CA-TEVA-2021-CA-1950118,TEVA,,,,,M,Y,,,20210908,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,198026461,DE,,,,,,,,,198026461,1,Product used for unknown indication
19802647,198026471,1,I,,20210830,20210908,20210908,EXP,,CA-TEVA-2021-CA-1950208,TEVA,,54,YR,A,M,Y,,,20210908,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,198026471,OT,,,,,,,,,198026471,1,HIV infection
19802649,198026491,1,I,,20210830,20210908,20210908,EXP,,CA-TEVA-2021-CA-1950210,TEVA,,54,YR,A,M,Y,,,20210908,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,198026491,OT,,,,,,,,,198026491,1,Bipolar disorder
19803160,198031601,1,I,,20210901,20210908,20210908,EXP,,JP-GLAXOSMITHKLINE-JP2021JPN188941,GLAXOSMITHKLINE,,,,,M,Y,,,20210908,,CN,JP,JP,EFAVIRENZ.,Blood HIV RNA increased;Pathogen resistance;Rash;Viraemia,198031601,OT,,,,,,,,,198031601,1,HIV infection
19803165,198031651,1,I,,20210901,20210908,20210908,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2021JPN188941,VIIV,,,,,M,Y,,,20210908,,CN,JP,JP,EFAVIRENZ.,Blood HIV RNA increased;Pathogen resistance;Rash;Viraemia,198031651,OT,,,,,,,,,198031651,1,HIV infection
19803650,198036501,1,I,,20210830,20210908,20210908,EXP,,CA-TEVA-2021-CA-1949955,TEVA,,,,,M,Y,,,20210908,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,198036501,HO,,,,,,,,,198036501,1,Product used for unknown indication
19804070,198040701,1,I,,20210831,20210908,20210908,EXP,,ZA-MYLANLABS-2021M1059873,MYLAN,"SEEDAT F, PATEL M, PHILLIP V, MOHAMED F, MARAIS AD, BLACKHURST DM, ET AL. HYPERLIPIDEMIC MYELOMA, A RARE FORM OF ACQUIRED DYSBETALIPOPROTEINEMIA, IN AN HIV SEROPOSITIVE AFRICAN FEMALE. CLIN?CHIM?ACTA 2021?520:71?75.",53,YR,,F,Y,,,20210908,,HP,ZA,ZA,EFAVIRENZ.,Type III hyperlipidaemia,198040701,HO,,,,,,,,,198040701,1,HIV infection
19806084,198060841,1,I,,20210830,20210908,20210908,EXP,,CA-TEVA-2021-CA-1950145,TEVA,,54,YR,A,M,Y,,,20210908,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,198060841,OT,,,,,,,,,198060841,1,Bipolar disorder
19806456,198064561,1,I,,20210830,20210908,20210908,EXP,,CA-TEVA-2021-CA-1950156,TEVA,,54,YR,A,M,Y,,,20210908,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,198064561,OT,,,,,,,,,198064561,1,HIV infection
19806457,198064571,1,I,,20210830,20210908,20210908,EXP,,CA-TEVA-2021-CA-1949398,TEVA,,54,YR,A,M,Y,,,20210908,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,198064571,OT,,,,,,,,,198064571,1,HIV infection
19806461,198064611,1,I,,20210824,20210908,20210908,EXP,,CA-ALVOGEN-2021-ALVOGEN-117432,ALVOGEN,,54,YR,,M,Y,,,20210908,,HP,CA,CA,EFAVIRENZ.,Depression;Drug interaction,198064611,OT,,,,,,,,,198064611,1,Bipolar disorder
19806583,198065831,1,I,,20210830,20210909,20210909,EXP,,IN-CIPLA (EU) LIMITED-2021IN06147,CIPLA,,,,,,Y,,,20210909,,HP,IN,IN,EFAVIRENZ.,Treatment failure,198065831,OT,,,198065831,1,201209,,,,198065831,1,HIV infection
19809871,198098711,1,I,,20210830,20210909,20210909,EXP,,CA-TEVA-2021-CA-1950163,TEVA,,,,,M,Y,,,20210909,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,198098711,OT,,,,,,,,,198098711,1,Product used for unknown indication
19810650,198106501,1,I,,20210830,20210909,20210909,EXP,,CA-TEVA-2021-CA-1950167,TEVA,,54,YR,A,M,Y,,,20210909,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,198106501,OT,,,,,,,,,198106501,1,Product used for unknown indication
19810653,198106531,1,I,,20210830,20210909,20210909,EXP,,CA-TEVA-2021-CA-1950091,TEVA,,,,,M,Y,,,20210909,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,198106531,DE,,,,,,,,,198106531,1,HIV infection
19810656,198106561,1,I,,20210830,20210909,20210909,EXP,,CA-TEVA-2021-CA-1949397,TEVA,,54,YR,A,M,Y,,,20210909,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,198106561,OT,,,,,,,,,198106561,1,HIV infection
19811793,198117931,1,I,,20210830,20210909,20210909,EXP,,CA-TEVA-2021-CA-1950104,TEVA,,,,,M,Y,,,20210909,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,198117931,DE,,,,,,,,,198117931,1,Product used for unknown indication
19811796,198117961,1,I,,20210830,20210909,20210909,EXP,,CA-TEVA-2021-CA-1950170,TEVA,,54,YR,A,M,Y,,,20210909,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,198117961,OT,,,,,,,,,198117961,1,HIV infection
19812823,198128231,1,I,,20210907,20210910,20210910,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2021JPN190174,VIIV,,,,,,Y,,,20210910,,CN,JP,JP,EFAVIRENZ.,Blood HIV RNA increased,198128231,OT,,,,,,,,,198128231,1,HIV infection
19813733,198137331,1,I,20210712,,20210907,20210907,DIR,,,FDA-CTU,,63,YR,,F,N,,,20210715,N,HP,US,US,SUSTIVA,Pruritus;Urticaria,,,198137331,HP,198137331,1,20210626,20210715,,,198137331,1,Staphylococcal infection
19813987,198139871,1,I,,20210830,20210909,20210909,EXP,,CA-TEVA-2021-CA-1950108,TEVA,,,,,M,Y,,,20210909,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,198139871,OT,,,,,,,,,198139871,1,Product used for unknown indication
19818448,198184481,1,I,,20210902,20210911,20210911,EXP,,CA-TEVA-2021-CA-1952115,TEVA,,,,,M,Y,,,20210911,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,198184481,OT,,,,,,,,,198184481,1,Product used for unknown indication
19819308,198193081,1,I,,20210830,20210913,20210913,EXP,,IN-CIPLA LTD.-2021IN06149,CIPLA,,,,,,Y,,,20210913,,HP,IN,IN,EFAVIRENZ.,Treatment failure,198193081,OT,,,198193081,1,200801,,,,198193081,1,HIV infection
19819331,198193311,1,I,,20210830,20210913,20210913,EXP,,IN-CIPLA (EU) LIMITED-2021IN06155,CIPLA,,,,,,Y,,,20210913,,HP,IN,IN,EFAVIRENZ.,Renal tubular acidosis,198193311,OT,,,198193311,1,201501,,,,198193311,1,HIV infection
19819354,198193541,1,I,,20210830,20210913,20210913,EXP,,IN-CIPLA (EU) LIMITED-2021IN06158,CIPLA,,,,,,Y,,,20210913,,HP,IN,IN,EFAVIRENZ.,Treatment failure,198193541,OT,,,198193541,1,201410,,,,198193541,1,HIV infection
19819663,198196631,1,I,,20210830,20210913,20210913,EXP,,IN-CIPLA (EU) LIMITED-2021IN06156,CIPLA,,,,,,Y,,,20210913,,HP,IN,IN,EFAVIRENZ.,Renal tubular acidosis,198196631,OT,,,198196631,1,201503,,,,198196631,1,HIV infection
19819688,198196881,1,I,,20210830,20210913,20210913,EXP,,IN-CIPLA (EU) LIMITED-2021IN06160,CIPLA,,,,,,Y,,,20210913,,HP,IN,IN,EFAVIRENZ.,Treatment failure,198196881,OT,,,198196881,1,201404,,,,198196881,1,HIV infection
19820307,198203071,1,I,,20210830,20210913,20210913,EXP,,IN-CIPLA LTD.-2021IN06150,CIPLA,,,,,,Y,,,20210913,,HP,IN,IN,EFAVIRENZ.,Treatment failure,198203071,OT,,,198203071,1,201101,,,,198203071,1,HIV infection
19820769,198207691,1,I,,20210831,20210913,20210913,EXP,,ZA-STRIDES ARCOLAB LIMITED-2021SP027461,STRIDES,"SEEDAT F, PATEL M, PHILLIP V, MOHAMED F, MARAIS AD, BLACKHURST DM, ET AL.. HYPERLIPIDEMIC MYELOMA, A RARE FORM OF ACQUIRED DYSBETALIPOPROTEINEMIA, IN AN HIV SEROPOSITIVE AFRICAN FEMALE. CLIN?CHIM?ACTA.. 2021?52071?52075",53,YR,,F,Y,,,20210913,,HP,ZA,ZA,EFAVIRENZ.,Type III hyperlipidaemia,198207691,HO,,,,,,,,,198207691,1,HIV infection
19824700,198247001,1,I,,20210831,20210914,20210914,EXP,,ZA-LUPIN PHARMACEUTICALS INC.-2021-17133,LUPIN,,53,YR,,F,Y,,,20210914,,HP,ZA,ZA,EFAVIRENZ.,Type III hyperlipidaemia,198247001,HO,,,,,,,,,198247001,1,HIV infection
19824774,198247741,1,I,,20210901,20210914,20210914,EXP,,IN-APPCO PHARMA LLC-2118328,APPCO PHARMA,"BELGAUMKAR VA, CHAVAN RB, SURYATALEY PR, SALUNKE AS, PATIL PP, BORADE SM. SYSTEMIC LUPUS ERYTHEMATOSUS IN HIV: AN INSIGHT INTO CLINICAL IMPLICATIONS AND MANAGEMENT. INDIAN JOURNAL OF SEXUALLY TRANSMITTED DISEASES AND AIDS. 2019 JAN? 40(1):64 DOI: 10.4103/IJSTD.IJSTD_26_18.",47,YR,,F,Y,,,20210914,,HP,IN,IN,EFAVIRENZ.,Systemic lupus erythematosus,198247741,OT,,,,,,,,,198247741,1,HIV infection
19827521,198275211,1,I,,20210908,20210914,20210914,EXP,,NL-MYLANLABS-2021M1060934,MYLAN,"KORTMANN W., VAN AGTMAEL MA., VAN DIESSEN J., KANEN BLJ., JAKOBS C., NANAYAKKARA PWB.. 5?OXOPROLINE AS A CAUSE OF HIGH ANION GAP METABOLIC ACIDOSIS: AN UNCOMMON CAUSE WITH COMMON RISK FACTORS. NETH J MED. 2008?66 (8):354?7",56,YR,,F,Y,47,KG,20210914,,HP,NL,NL,EFAVIRENZ.,Metabolic acidosis;Pyroglutamate increased,198275211,OT,,,,,,,,,198275211,1,Urinary tract infection
19835641,198356411,1,I,,20210914,20210915,20210915,EXP,,US-GILEAD-2021-0548505,GILEAD,,,,A,M,Y,,,20210915,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebrovascular accident,198356411,HO,,,,,,,,,198356411,1,Product used for unknown indication
19837616,198376161,1,I,20210727,20210907,20210916,20210916,EXP,,TH-SA-2021SA300285,SANOFI AVENTIS,,28,YR,A,M,Y,,,20210916,,HP,TH,TH,EFAVIRENZ.,Anosmia;COVID-19;Cough;SARS-CoV-2 test positive,198376161,HO,,,198376161,1,20210322,20210608,,,198376161,1,Tuberculosis
19838200,198382001,1,I,,20210913,20210916,20210916,EXP,,CA-GILEAD-2021-0548506,GILEAD,,32,YR,A,M,Y,,,20210916,,HP,CA,CA,EFAVIRENZ.,Genotype drug resistance test positive;Therapeutic product effect incomplete,198382001,OT,,,,,,,,,198382001,1,HIV infection
19840985,198409851,1,I,,20210913,20210916,20210916,EXP,,CA-ASTRAZENECA-2021A724489,ASTRAZENECA,,54,YR,,M,Y,,,20210916,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,198409851,OT,,,,,,,,,198409851,1,Bipolar disorder
19844479,198444791,1,I,,20210913,20210916,20210916,EXP,,CA-ASTRAZENECA-2021A724480,ASTRAZENECA,,54,YR,,M,Y,,,20210916,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,198444791,DE,,,,,,,,,198444791,1,Bipolar disorder
19845057,198450571,1,I,,20210910,20210916,20210916,EXP,,ZA-GILEAD-2021-0548799,GILEAD,"MANICKCHUND N, DU PLESSIS C, JOHN MA, MANZINI TC, MOOSA M?YS. A CASE SERIES OF EMTRICITABINE?INDUCED PURE RED CELL APLASIA. UNK. 2021?22(1):1?4. DOI:10.4102/SAJHIVMED.V22I1.1271",48,YR,A,F,Y,,,20210916,,HP,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,198450571,OT,,,,,,,,,198450571,1,HIV infection
19845091,198450911,1,I,,20210910,20210916,20210916,EXP,,ZA-GILEAD-2021-0548800,GILEAD,"MANICKCHUND N, DU PLESSIS C, JOHN MA, MANZINI TC, MOOSA M?YS. A CASE SERIES OF EMTRICITABINE?INDUCED PURE RED CELL APLASIA. UNK. 2021?22(1):1?4. DOI:10.4102/SAJHIVMED.V22I1.1271",55,YR,A,F,Y,,,20210916,,HP,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,198450911,OT,,,,,,,,,198450911,1,HIV infection
19845099,198450991,1,I,,20210910,20210916,20210916,EXP,,ZA-GILEAD-2021-0548801,GILEAD,"MANICKCHUND N, DU PLESSIS C, JOHN MA, MANZINI TC, MOOSA M?YS. A CASE SERIES OF EMTRICITABINE?INDUCED PURE RED CELL APLASIA. UNK. 2021?22(1):1?4. DOI:10.4102/SAJHIVMED.V22I1.1271",35,YR,A,F,Y,,,20210916,,HP,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,198450991,OT,,,,,,,,,198450991,1,HIV infection
19845107,198451071,1,I,,20210910,20210916,20210916,EXP,,ZA-GILEAD-2021-0548802,GILEAD,"MANICKCHUND N, DU PLESSIS C, JOHN MA, MANZINI TC, MOOSA M?YS. A CASE SERIES OF EMTRICITABINE?INDUCED PURE RED CELL APLASIA. UNK. 2021?22(1):1?4. DOI:10.4102/SAJHIVMED.V22I1.1271",23,YR,A,F,Y,,,20210916,,HP,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,198451071,OT,,,,,,,,,198451071,1,HIV infection
19849692,198496921,1,I,,20210910,20210917,20210917,EXP,,ZA-GILEAD-2021-0548136,GILEAD,"MANICKCHUND N, DU PLESSIS C, JOHN MA, MANZINI TC, MOOSA M?YS. A CASE SERIES OF EMTRICITABINE?INDUCED PURE RED CELL APLASIA. UNK. 2021?22(1):1?4. DOI:10.4102/SAJHIVMED.V22I1.1271",61,YR,A,F,Y,,,20210917,,HP,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,198496921,OT,,,,,,,,,198496921,1,HIV infection
19854662,198546622,2,F,,20210913,20210920,20210924,EXP,,ZA-AUROBINDO-AUR-APL-2021-038920,AUROBINDO,,53,YR,,F,Y,,,20210924,,HP,ZA,ZA,EFAVIRENZ.,Plasma cell myeloma;Type III hyperlipidaemia;Xanthoma,198546622,OT,,,,,,,,,198546622,1,HIV infection
19856526,198565261,1,I,,20210913,20210920,20210920,EXP,,CA-APOTEX-2021AP042592,APOTEX,,10,YR,,F,Y,,,20210920,,CN,CA,CA,EFAVIRENZ.,Chills;Disease recurrence;Nephropathy toxic,198565261,OT,,,,,,,,,198565261,1,Antiretroviral therapy
19856529,198565291,1,I,202006,20210914,20210920,20210920,EXP,,DE-MYLANLABS-2021M1063808,MYLAN,,,,,M,Y,,,20210920,,HP,DE,DE,EFAVIRENZ.,Hypophosphataemia;Renal tubular dysfunction;Vitamin D deficiency,198565291,OT,,,198565291,1,200706,201704,,,198565291,1,HIV infection
19857566,198575661,1,I,,20210913,20210921,20210921,EXP,,CA-ASTRAZENECA-2021A724592,ASTRAZENECA,,54,YR,,M,Y,,,20210921,,HP,CA,CA,EFAVIRENZ.,Depression;Drug interaction;Loss of personal independence in daily activities,198575661,OT,,,,,,,,,198575661,1,Bipolar disorder
19858950,198589501,1,I,2004,20210915,20210920,20210920,EXP,,ES-MYLANLABS-2021M1063042,MYLAN,,66,YR,,M,Y,,,20210920,,MD,ES,ES,EFAVIRENZ.,Drug ineffective;Treatment failure,198589501,OT,,,,,,,,,198589501,1,HIV infection
19867567,198675671,1,I,,20210915,20210922,20210922,EXP,,CA-GLAXOSMITHKLINE-CA2021AMR196454,GLAXOSMITHKLINE,,10,YR,,F,Y,,,20210922,,HP,CA,CA,EFAVIRENZ.,Chills;Disease recurrence;Nephropathy toxic,198675671,OT,,,,,,,,,198675671,1,Antiretroviral therapy
19867673,198676731,1,I,,20210915,20210922,20210922,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021AMR196454,VIIV,,10,YR,,F,Y,,,20210922,,HP,CA,CA,EFAVIRENZ.,Chills;Disease recurrence;Nephropathy toxic,198676731,OT,,,,,,,,,198676731,1,Antiretroviral therapy
19876668,198766681,1,I,,20210920,20210924,20210924,EXP,,CA-BAUSCH-BL-2021-032520,BAUSCH AND LOMB,,54,YR,,M,Y,,,20210924,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,198766681,OT,,,,,,,,,198766681,1,Product used for unknown indication
19876853,198768531,1,I,2004,20210920,20210923,20210923,EXP,,PT-MYLANLABS-2021M1064463,MYLAN,,55,YR,,F,Y,,,20210923,,MD,PT,PT,EFAVIRENZ.,Major depression;Neuropathy peripheral,198768531,OT,,,198768531,1,2011,2014,,,198768531,1,HIV infection
19876897,198768971,1,I,,20210920,20210924,20210924,EXP,,CA-BAUSCH-BL-2021-032511,BAUSCH AND LOMB,,54,YR,,M,Y,,,20210924,,HP,CA,CA,EFAVIRENZ.,Depression;Drug interaction;Loss of personal independence in daily activities,198768971,OT,,,,,,,,,198768971,1,Bipolar disorder
19879103,198791031,1,I,,20210412,20210924,20210924,EXP,,SE-AUROBINDO-AUR-APL-2021-015949,AUROBINDO,,66,YR,,M,Y,,,20210924,,HP,SE,SE,EFAVIRENZ.,Potentiating drug interaction,198791031,OT,,,,,,,,,198791031,1,Product used for unknown indication
19883492,198834921,1,I,,20210921,20210926,20210926,EXP,,AU-ABBVIE-21K-008-4090300-00,ABBVIE,,,,,F,Y,,,20210926,,CN,AU,AU,EFAVIRENZ.,Behaviour disorder;Central nervous system inflammation;Cerebellar syndrome;Chorea;Confusional state;Disorientation;Dysarthria;Dysdiadochokinesis;Gait disturbance;HIV-associated neurocognitive disorder;Hypophagia;Loss of personal independence in daily activities;Magnetic resonance imaging head abnormal;Meningitis viral;Meningoencephalitis viral;Parainfluenzae virus infection;Pathogen resistance;Rhinitis;Treatment noncompliance;Viral mutation identified,198834921,OT,,,,,,,,,198834921,1,Product used for unknown indication
19884559,198845591,1,I,,20210915,20210927,20210927,EXP,,CA-AUROBINDO-AUR-APL-2021-039967,AUROBINDO,,10,YR,,F,Y,,,20210927,,HP,CA,CA,EFAVIRENZ.,Chills;Disease recurrence;Nephropathy toxic,198845591,OT,,,,,,,,,198845591,1,Antiretroviral therapy
19884907,198849071,1,I,,20210916,20210927,20210927,EXP,,ZA-MACLEODS PHARMA UK LTD-MAC2021032761,MACLEODS,,,,,,Y,,,20210927,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,198849071,OT,,,,,,,,,198849071,1,Antiretroviral therapy
19885066,198850661,1,I,,20210916,20210927,20210927,EXP,,ZA-MACLEODS PHARMA UK LTD-MAC2021032763,MACLEODS,,,,,,Y,,,20210927,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,198850661,OT,,,,,,,,,198850661,1,Antiretroviral therapy
19885196,198851961,1,I,,20210916,20210927,20210927,EXP,,ZA-MACLEODS PHARMA UK LTD-MAC2021032764,MACLEODS,,,,,,Y,,,20210927,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,198851961,OT,,,,,,,,,198851961,1,Antiretroviral therapy
19885285,198852851,1,I,,20210916,20210927,20210927,EXP,,ZA-MACLEODS PHARMA UK LTD-MAC2021032765,MACLEODS,,,,,,Y,,,20210927,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,198852851,OT,,,,,,,,,198852851,1,Antiretroviral therapy
19885394,198853941,1,I,,20210916,20210927,20210927,EXP,,ZA-MACLEODS PHARMA UK LTD-MAC2021032766,MACLEODS,,,,,,Y,,,20210927,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,198853941,OT,,,,,,,,,198853941,1,HIV infection
19885531,198855311,1,I,,20210916,20210927,20210927,EXP,,ZA-MACLEODS PHARMA UK LTD-MAC2021032762,MACLEODS,,,,,,Y,,,20210927,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,198855311,OT,,,,,,,,,198855311,1,Antiretroviral therapy
19889360,198893601,1,I,202006,20210914,20210928,20210928,PER,,DE-LUPIN PHARMACEUTICALS INC.-2021-18149,LUPIN,,,,,M,Y,,,20210928,,HP,DE,DE,EFAVIRENZ.,Hypophosphataemia;Renal tubular dysfunction;Vitamin D deficiency,198893601,OT,,,198893601,1,2015,201704,,,198893601,1,HIV infection
19889985,198899851,1,I,,20210914,20210927,20210927,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2021GSK195185,VIIV,"SONEJA M, AGGARWAL A, KODAN P, GUPTA N. HUMAN IMMUNODEFICIENCY VIRUS INFECTION WITH MULTIPLE OPPORTUNISTIC INFECTIONS: LESSONS LEARNT FROM A NON?ADHERENT PATIENT. OXFORD MEDICAL CASE REPORTS. 2021?2021 (3):79?81",50,YR,,M,Y,,,20210927,,HP,IN,IN,EFAVIRENZ.,Blood electrolytes abnormal;Cachexia;Condition aggravated;Cryptosporidiosis infection;Cytomegalovirus oesophagitis;Dehydration;Diarrhoea;Dysphagia;Erythema;Ichthyosis;Oesophageal candidiasis;Oral candidiasis;Oral mucosal erythema;Punctate keratitis;SJS-TEN overlap;Skin lesion;Therapy non-responder;Treatment noncompliance,198899851,HO,,,,,,,,,198899851,1,HIV infection
19889986,198899861,1,I,,20210914,20210927,20210927,EXP,,IN-GLAXOSMITHKLINE-IN2021GSK195185,GLAXOSMITHKLINE,"SONEJA M, AGGARWAL A, KODAN P, GUPTA N. HUMAN IMMUNODEFICIENCY VIRUS INFECTION WITH MULTIPLE OPPORTUNISTIC INFECTIONS: LESSONS LEARNT FROM A NON?ADHERENT PATIENT. OXFORD MEDICAL CASE REPORTS. 2021?2021 (3):79?81",50,YR,,M,Y,,,20210927,,HP,IN,IN,EFAVIRENZ.,Blood electrolytes abnormal;Cachexia;Condition aggravated;Cryptosporidiosis infection;Cytomegalovirus oesophagitis;Dehydration;Diarrhoea;Dysphagia;Erythema;Ichthyosis;Oesophageal candidiasis;Oral candidiasis;Oral mucosal erythema;Punctate keratitis;SJS-TEN overlap;Skin lesion;Therapy non-responder;Treatment noncompliance,198899861,OT,,,,,,,,,198899861,1,HIV infection
19890987,198909871,1,I,,20210921,20210928,20210928,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2021EME201026,VIIV,,58,YR,,M,Y,,,20210928,,CN,GB,GB,EFAVIRENZ.,Renal failure,198909871,OT,,,198909871,1,20120601,,,,198909871,1,HIV infection
19894699,198946991,1,I,,20210921,20210929,20210929,EXP,,CA-APOTEX-2021AP043233,APOTEX,,54,YR,,M,Y,,,20210929,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,198946991,OT,,,,,,,,,198946991,1,HIV infection
19896069,198960691,1,I,,20210927,20210929,20210929,EXP,,CH-GILEAD-2021-0550396,GILEAD,,,,A,M,Y,,,20210929,,MD,CH,CH,EFAVIRENZ.,Blood creatinine increased;Disseminated leishmaniasis;Glycosuria;Haemoglobin decreased;Hepatosplenomegaly;Renal failure;Visceral leishmaniasis;Weight decreased,198960691,OT,,,,,,,,,198960691,1,HIV infection
19898315,198983151,1,I,,20210921,20210930,20210930,EXP,,CA-APOTEX-2021AP043204,APOTEX,,32,YR,,M,Y,,,20210930,,CN,CA,CA,EFAVIRENZ.,Genotype drug resistance test positive;Therapeutic product effect incomplete,198983151,OT,,,,,,,,,198983151,1,HIV infection
19901857,199018571,1,I,,20210913,20210930,20210930,EXP,,IN-CIPLA LTD.-2021IN06388,CIPLA,,,,,,Y,,,20210930,,HP,IN,IN,EFAVIRENZ.,Depression;Drug interaction;Euphoric mood;Insomnia;Irritability;Logorrhoea;Therapy non-responder,199018571,OT,,,,,,,,,199018571,1,HIV infection
19904740,199047401,1,I,,20210927,20210930,20210930,EXP,,KR-VIIV HEALTHCARE LIMITED-KR2021APC203508,VIIV,,60,YR,,F,Y,62.8,KG,20210930,,MD,KR,KR,EFAVIRENZ.,Oesophageal candidiasis,199047401,OT,,,199047401,1,20140310,20140323,,,199047401,1,HIV infection
19904745,199047451,1,I,,20210927,20210930,20210930,EXP,,KR-GLAXOSMITHKLINE-KR2021APC203508,GLAXOSMITHKLINE,,60,YR,,F,Y,62.8,KG,20210930,,MD,KR,KR,EFAVIRENZ.,Oesophageal candidiasis,199047451,OT,,,199047451,1,20140310,20140323,,,199047451,1,HIV infection
4150515,41505154,4,F,200203,20210705,20040607,20210712,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12605176,BRISTOL MYERS SQUIBB,"PEYRIERE H, REYNES J, ROUANET I, DANIEL N, DE BOEVER, MAUBOUSSIN JM, ET AL. RENAL TUBULAR DYSFUNCTION ASSOCIATED WITH TENOFOVIR THERAPY REPORT OF 7 CASES. J ACQUIR IMMUNE DEFIC SYNDR. 2004?35(3):269?73",56,YR,,F,Y,56,KG,20210712,,HP,FR,FR,EFAVIRENZ.,Pain in extremity;Renal tubular dysfunction,41505154,OT,,,41505154,1,200105,2002,,,41505154,1,HIV infection
6753908,675390810,10,F,20060602,20210820,20080911,20210830,EXP,,CA-MERCK-0809CAN00002,MERCK,,44,YR,,M,Y,,,20210830,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,675390810,HO,,,675390810,1,20070626,20070522,,,675390810,1,HIV infection
7302622,730262240,40,F,,20210907,20100302,20210915,EXP,,CA-MERCK-0907CAN00093,MERCK,,52,YR,,M,Y,,,20210915,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Blood lactic acid increased;Diplopia;Dysphagia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,730262240,OT,,,730262240,12,200802,200802,,,730262240,1,HIV infection
